{"cells":[{"source":"<a href=\"https://www.kaggle.com/code/danielansted/biotech-clustering?scriptVersionId=183536243\" target=\"_blank\"><img align=\"left\" alt=\"Kaggle\" title=\"Open in Kaggle\" src=\"https://kaggle.com/static/images/open-in-kaggle.svg\"></a>","metadata":{},"cell_type":"markdown"},{"cell_type":"code","execution_count":1,"id":"0a4475f2","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:30.600118Z","iopub.status.busy":"2024-06-14T17:30:30.599714Z","iopub.status.idle":"2024-06-14T17:30:34.413944Z","shell.execute_reply":"2024-06-14T17:30:34.412866Z"},"id":"Ic44mOZfK_bh","outputId":"2a56ce7c-1c72-4d83-ed0d-c2748ac5f402","papermill":{"duration":3.834471,"end_time":"2024-06-14T17:30:34.416672","exception":false,"start_time":"2024-06-14T17:30:30.582201","status":"completed"},"tags":[]},"outputs":[],"source":["import warnings\n","from sklearn.metrics.pairwise import cosine_distances\n","from sklearn.manifold import TSNE\n","from sklearn.cluster import KMeans\n","import matplotlib.pyplot as plt\n","import plotly.express as px\n","import plotly.graph_objects as go\n","import gc\n","from datetime import datetime\n","from sklearn.preprocessing import MaxAbsScaler, StandardScaler, OneHotEncoder\n","from sklearn.metrics import accuracy_score\n","import numpy as np\n","import pandas as pd\n","import nltk\n","from nltk.corpus import stopwords\n","from nltk.tokenize import word_tokenize\n","from nltk.stem import WordNetLemmatizer\n","import os\n","import string\n","from sklearn.feature_extraction.text import TfidfVectorizer\n","from sklearn.decomposition import TruncatedSVD\n","\n","\n","\n","\n","warnings.filterwarnings('ignore')"]},{"cell_type":"markdown","id":"b507a0a1","metadata":{"papermill":{"duration":0.016065,"end_time":"2024-06-14T17:30:34.449072","exception":false,"start_time":"2024-06-14T17:30:34.433007","status":"completed"},"tags":[]},"source":["# Import the Data\n","##### I know this dataset is in Kaggle, but I was responsible for the initial dataset collection as well. See https://github.com/Noob1701/Clin_Trials_Clustering for data collection notebook"]},{"cell_type":"code","execution_count":2,"id":"0a93b4b8","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:34.483022Z","iopub.status.busy":"2024-06-14T17:30:34.482423Z","iopub.status.idle":"2024-06-14T17:30:35.101327Z","shell.execute_reply":"2024-06-14T17:30:35.100061Z"},"papermill":{"duration":0.638155,"end_time":"2024-06-14T17:30:35.103871","exception":false,"start_time":"2024-06-14T17:30:34.465716","status":"completed"},"tags":[]},"outputs":[{"name":"stdout","output_type":"stream","text":["[nltk_data] Downloading package wordnet to /kaggle/working/...\n","Archive:  /kaggle/working/corpora/wordnet.zip\n","   creating: /kaggle/working/corpora/wordnet/\n","  inflating: /kaggle/working/corpora/wordnet/lexnames  \n","  inflating: /kaggle/working/corpora/wordnet/data.verb  \n","  inflating: /kaggle/working/corpora/wordnet/index.adv  \n","  inflating: /kaggle/working/corpora/wordnet/adv.exc  \n","  inflating: /kaggle/working/corpora/wordnet/index.verb  \n","  inflating: /kaggle/working/corpora/wordnet/cntlist.rev  \n","  inflating: /kaggle/working/corpora/wordnet/data.adj  \n","  inflating: /kaggle/working/corpora/wordnet/index.adj  \n","  inflating: /kaggle/working/corpora/wordnet/LICENSE  \n","  inflating: /kaggle/working/corpora/wordnet/citation.bib  \n","  inflating: /kaggle/working/corpora/wordnet/noun.exc  \n","  inflating: /kaggle/working/corpora/wordnet/verb.exc  \n","  inflating: /kaggle/working/corpora/wordnet/README  \n","  inflating: /kaggle/working/corpora/wordnet/index.sense  \n","  inflating: /kaggle/working/corpora/wordnet/data.noun  \n","  inflating: /kaggle/working/corpora/wordnet/data.adv  \n","  inflating: /kaggle/working/corpora/wordnet/index.noun  \n","  inflating: /kaggle/working/corpora/wordnet/adj.exc  \n"]}],"source":["import nltk\n","import subprocess\n","\n","# Download and unzip wordnet\n","try:\n","    nltk.data.find('wordnet.zip')\n","except:\n","    nltk.download('wordnet', download_dir='/kaggle/working/')\n","    command = \"unzip /kaggle/working/corpora/wordnet.zip -d /kaggle/working/corpora\"\n","    subprocess.run(command.split())\n","    nltk.data.path.append('/kaggle/working/')\n","\n","from nltk.corpus import wordnet"]},{"cell_type":"code","execution_count":3,"id":"09c2c6d1","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:35.138025Z","iopub.status.busy":"2024-06-14T17:30:35.13763Z","iopub.status.idle":"2024-06-14T17:30:35.152721Z","shell.execute_reply":"2024-06-14T17:30:35.151281Z"},"papermill":{"duration":0.034984,"end_time":"2024-06-14T17:30:35.155172","exception":false,"start_time":"2024-06-14T17:30:35.120188","status":"completed"},"tags":[]},"outputs":[{"name":"stdout","output_type":"stream","text":["/kaggle/input/clinicaltrials-gov-clinical-trials-dataset/clin_trials.csv\n"]}],"source":["\n","for dirname, _, filenames in os.walk('/kaggle/input'):\n","    for filename in filenames:\n","        print(os.path.join(dirname, filename))"]},{"cell_type":"code","execution_count":4,"id":"df397170","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:35.188202Z","iopub.status.busy":"2024-06-14T17:30:35.187837Z","iopub.status.idle":"2024-06-14T17:30:47.416562Z","shell.execute_reply":"2024-06-14T17:30:47.415411Z"},"id":"SUaTovbuFXFR","papermill":{"duration":12.248069,"end_time":"2024-06-14T17:30:47.419013","exception":false,"start_time":"2024-06-14T17:30:35.170944","status":"completed"},"tags":[]},"outputs":[{"data":{"text/html":["<div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>Organization Full Name</th>\n","      <th>Organization Class</th>\n","      <th>Responsible Party</th>\n","      <th>Brief Title</th>\n","      <th>Full Title</th>\n","      <th>Overall Status</th>\n","      <th>Start Date</th>\n","      <th>Standard Age</th>\n","      <th>Conditions</th>\n","      <th>Primary Purpose</th>\n","      <th>Interventions</th>\n","      <th>Intervention Description</th>\n","      <th>Study Type</th>\n","      <th>Phases</th>\n","      <th>Outcome Measure</th>\n","      <th>Medical Subject Headings</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <th>0</th>\n","      <td>Montefiore Medical Center</td>\n","      <td>OTHER</td>\n","      <td>SPONSOR</td>\n","      <td>Kinesiotape for Edema After Bilateral Total Kn...</td>\n","      <td>Effect of Kinesiotaping on Edema Management, P...</td>\n","      <td>COMPLETED</td>\n","      <td>2021-10-18</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Arthroplasty Complications, Arthroplasty, Repl...</td>\n","      <td>TREATMENT</td>\n","      <td>Kinesio(R)Tape for edema control</td>\n","      <td>Kinesio(R)Tape is an elastic, cotton tape with...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>NaN</td>\n","      <td>Change from baseline and during 1-2-day time i...</td>\n","      <td>Edema</td>\n","    </tr>\n","  </tbody>\n","</table>\n","</div>"],"text/plain":["      Organization Full Name Organization Class Responsible Party  \\\n","0  Montefiore Medical Center              OTHER           SPONSOR   \n","\n","                                         Brief Title  \\\n","0  Kinesiotape for Edema After Bilateral Total Kn...   \n","\n","                                          Full Title Overall Status  \\\n","0  Effect of Kinesiotaping on Edema Management, P...      COMPLETED   \n","\n","   Start Date       Standard Age  \\\n","0  2021-10-18  ADULT OLDER_ADULT   \n","\n","                                          Conditions Primary Purpose  \\\n","0  Arthroplasty Complications, Arthroplasty, Repl...       TREATMENT   \n","\n","                      Interventions  \\\n","0  Kinesio(R)Tape for edema control   \n","\n","                            Intervention Description      Study Type Phases  \\\n","0  Kinesio(R)Tape is an elastic, cotton tape with...  INTERVENTIONAL    NaN   \n","\n","                                     Outcome Measure Medical Subject Headings  \n","0  Change from baseline and during 1-2-day time i...                    Edema  "]},"execution_count":4,"metadata":{},"output_type":"execute_result"}],"source":["'''n = 496615 #number of records in file\n","s = 100000 #desired sample size\n","\n","n = sum(1 for line in open('/kaggle/input/clinicaltrials-gov-clinical-trials-dataset/clin_trials.csv')) - 1 #number of records in file (excludes header)\n","s = 10000 #desired sample size\n","skip = sorted(random.sample(range(1,n+1),n-s)) #the 0-indexed header will not be included in the skip list'''\n","clin_trials = pd.read_csv('/kaggle/input/clinicaltrials-gov-clinical-trials-dataset/clin_trials.csv')\n","clin_trials = clin_trials.drop('Unnamed: 0', axis = 1)\n","clin_trials_ro = clin_trials\n","clin_trials.head(1)"]},{"cell_type":"markdown","id":"59390d71","metadata":{"papermill":{"duration":0.01638,"end_time":"2024-06-14T17:30:47.451261","exception":false,"start_time":"2024-06-14T17:30:47.434881","status":"completed"},"tags":[]},"source":["# Limiting Data to Sponsor and Industry"]},{"cell_type":"code","execution_count":5,"id":"b18903b2","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:47.485212Z","iopub.status.busy":"2024-06-14T17:30:47.484813Z","iopub.status.idle":"2024-06-14T17:30:47.749833Z","shell.execute_reply":"2024-06-14T17:30:47.748819Z"},"id":"iN8Xq9VFLVNo","outputId":"77407cdb-fa31-4c35-bbfd-b490a1688973","papermill":{"duration":0.284451,"end_time":"2024-06-14T17:30:47.752037","exception":false,"start_time":"2024-06-14T17:30:47.467586","status":"completed"},"tags":[]},"outputs":[{"name":"stdout","output_type":"stream","text":["496615\n","100864\n"]},{"data":{"text/plain":["Index(['Organization Full Name', 'Organization Class', 'Responsible Party',\n","       'Brief Title', 'Full Title', 'Overall Status', 'Start Date',\n","       'Standard Age', 'Conditions', 'Primary Purpose', 'Interventions',\n","       'Intervention Description', 'Study Type', 'Phases', 'Outcome Measure',\n","       'Medical Subject Headings'],\n","      dtype='object')"]},"execution_count":5,"metadata":{},"output_type":"execute_result"}],"source":["pd.set_option('display.max_columns', None)\n","print(len(clin_trials))\n","clin_trials = clin_trials[clin_trials['Responsible Party'] == 'SPONSOR']\n","clin_trials = clin_trials[clin_trials['Organization Class'] == 'INDUSTRY']\n","clin_trials = clin_trials.reset_index(drop = True)\n","print(len(clin_trials))\n","clin_trials.columns"]},{"cell_type":"markdown","id":"33c39d8f","metadata":{"papermill":{"duration":0.016077,"end_time":"2024-06-14T17:30:47.784332","exception":false,"start_time":"2024-06-14T17:30:47.768255","status":"completed"},"tags":[]},"source":["# Data Preprocessing"]},{"cell_type":"code","execution_count":6,"id":"410825fb","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:47.818088Z","iopub.status.busy":"2024-06-14T17:30:47.817708Z","iopub.status.idle":"2024-06-14T17:30:47.823079Z","shell.execute_reply":"2024-06-14T17:30:47.821983Z"},"papermill":{"duration":0.025084,"end_time":"2024-06-14T17:30:47.825477","exception":false,"start_time":"2024-06-14T17:30:47.800393","status":"completed"},"tags":[]},"outputs":[],"source":["formats = [\n","    \"%Y-%m-%d\",             # 2023-06-01\n","    \"%d/%m/%Y %H:%M:%S\",    # 01/06/2023 14:45:00\n","    \"%B %d, %Y\",            # June 1, 2023\n","    \"%Y.%m.%d AD at %H:%M:%S\", # 2023.06.01 AD at 14:45:00\n","    \"%d-%b-%Y\",             # 01-Jun-2023\n","    \"%Y/%m/%d %H:%M\",       # 2023/06/01 14:45\n","    \"%d/%m/%Y\"              # 15/08/2023\n","]"]},{"cell_type":"code","execution_count":7,"id":"6342af09","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:47.860341Z","iopub.status.busy":"2024-06-14T17:30:47.859918Z","iopub.status.idle":"2024-06-14T17:30:47.865888Z","shell.execute_reply":"2024-06-14T17:30:47.864597Z"},"papermill":{"duration":0.026364,"end_time":"2024-06-14T17:30:47.868194","exception":false,"start_time":"2024-06-14T17:30:47.84183","status":"completed"},"tags":[]},"outputs":[],"source":["def parse_mixed_date(date_str):\n","    '''Parses dates regardless of format\n","    Parameter: A date string\n","    Returns: datetime or if string does not match any format pd.NaT'''\n","    \n","    for fmt in formats:\n","        try:\n","            return datetime.strptime(date_str, fmt)\n","        except ValueError:\n","            continue\n","    return pd.NaT"]},{"cell_type":"code","execution_count":8,"id":"f82fa35f","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:47.902623Z","iopub.status.busy":"2024-06-14T17:30:47.901577Z","iopub.status.idle":"2024-06-14T17:30:48.730876Z","shell.execute_reply":"2024-06-14T17:30:48.729733Z"},"papermill":{"duration":0.849027,"end_time":"2024-06-14T17:30:48.733318","exception":false,"start_time":"2024-06-14T17:30:47.884291","status":"completed"},"tags":[]},"outputs":[{"data":{"text/html":["<div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>Organization Full Name</th>\n","      <th>Organization Class</th>\n","      <th>Responsible Party</th>\n","      <th>Brief Title</th>\n","      <th>Full Title</th>\n","      <th>Overall Status</th>\n","      <th>Start Date</th>\n","      <th>Standard Age</th>\n","      <th>Conditions</th>\n","      <th>Primary Purpose</th>\n","      <th>Interventions</th>\n","      <th>Intervention Description</th>\n","      <th>Study Type</th>\n","      <th>Phases</th>\n","      <th>Outcome Measure</th>\n","      <th>Medical Subject Headings</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <th>count</th>\n","      <td>100864</td>\n","      <td>100864</td>\n","      <td>100864</td>\n","      <td>100864</td>\n","      <td>100864</td>\n","      <td>100864</td>\n","      <td>100864</td>\n","      <td>100864</td>\n","      <td>100864</td>\n","      <td>100864</td>\n","      <td>100864</td>\n","      <td>100864</td>\n","      <td>100864</td>\n","      <td>84897</td>\n","      <td>100864</td>\n","      <td>100864</td>\n","    </tr>\n","    <tr>\n","      <th>unique</th>\n","      <td>11732</td>\n","      <td>1</td>\n","      <td>1</td>\n","      <td>100346</td>\n","      <td>98334</td>\n","      <td>13</td>\n","      <td>6635</td>\n","      <td>6</td>\n","      <td>32146</td>\n","      <td>10</td>\n","      <td>78488</td>\n","      <td>79843</td>\n","      <td>3</td>\n","      <td>8</td>\n","      <td>87496</td>\n","      <td>12406</td>\n","    </tr>\n","    <tr>\n","      <th>top</th>\n","      <td>GlaxoSmithKline</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>Sun Protection Factor Assay</td>\n","      <td>Unknown</td>\n","      <td>COMPLETED</td>\n","      <td>Unknown</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Healthy</td>\n","      <td>TREATMENT</td>\n","      <td>Unknown</td>\n","      <td>Unknown</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE1</td>\n","      <td>Unknown</td>\n","      <td>Unknown</td>\n","    </tr>\n","    <tr>\n","      <th>freq</th>\n","      <td>3374</td>\n","      <td>100864</td>\n","      <td>100864</td>\n","      <td>14</td>\n","      <td>1548</td>\n","      <td>65002</td>\n","      <td>809</td>\n","      <td>70110</td>\n","      <td>4052</td>\n","      <td>66338</td>\n","      <td>4828</td>\n","      <td>9029</td>\n","      <td>85847</td>\n","      <td>22969</td>\n","      <td>1176</td>\n","      <td>17831</td>\n","    </tr>\n","  </tbody>\n","</table>\n","</div>"],"text/plain":["       Organization Full Name Organization Class Responsible Party  \\\n","count                  100864             100864            100864   \n","unique                  11732                  1                 1   \n","top           GlaxoSmithKline           INDUSTRY           SPONSOR   \n","freq                     3374             100864            100864   \n","\n","                        Brief Title Full Title Overall Status Start Date  \\\n","count                        100864     100864         100864     100864   \n","unique                       100346      98334             13       6635   \n","top     Sun Protection Factor Assay    Unknown      COMPLETED    Unknown   \n","freq                             14       1548          65002        809   \n","\n","             Standard Age Conditions Primary Purpose Interventions  \\\n","count              100864     100864          100864        100864   \n","unique                  6      32146              10         78488   \n","top     ADULT OLDER_ADULT    Healthy       TREATMENT       Unknown   \n","freq                70110       4052           66338          4828   \n","\n","       Intervention Description      Study Type  Phases Outcome Measure  \\\n","count                    100864          100864   84897          100864   \n","unique                    79843               3       8           87496   \n","top                     Unknown  INTERVENTIONAL  PHASE1         Unknown   \n","freq                       9029           85847   22969            1176   \n","\n","       Medical Subject Headings  \n","count                    100864  \n","unique                    12406  \n","top                     Unknown  \n","freq                      17831  "]},"execution_count":8,"metadata":{},"output_type":"execute_result"}],"source":["clin_trials.describe()"]},{"cell_type":"code","execution_count":9,"id":"a04b7389","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:48.76771Z","iopub.status.busy":"2024-06-14T17:30:48.767229Z","iopub.status.idle":"2024-06-14T17:30:48.797239Z","shell.execute_reply":"2024-06-14T17:30:48.796146Z"},"papermill":{"duration":0.050033,"end_time":"2024-06-14T17:30:48.799637","exception":false,"start_time":"2024-06-14T17:30:48.749604","status":"completed"},"tags":[]},"outputs":[{"data":{"text/plain":["Medical Subject Headings\n","Unknown                                                                                                                                                                                                  17831\n","Neoplasms                                                                                                                                                                                                 2197\n","Diabetes Mellitus Diabetes Mellitus, Type 2                                                                                                                                                               1886\n","Breast Neoplasms                                                                                                                                                                                          1322\n","Arthritis Arthritis, Rheumatoid                                                                                                                                                                           1071\n","                                                                                                                                                                                                         ...  \n","Substance-Related Disorders Alcoholism Alcohol Drinking                                                                                                                                                      1\n","Heart Diseases Arrhythmias, Cardiac                                                                                                                                                                          1\n","Rectal Neoplasms Cancer Pain                                                                                                                                                                                 1\n","Lymphoma Leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid Lymphoma, Large B-Cell, Diffuse Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Follicular Lymphoma, Mantle-Cell        1\n","Dermatitis, Atopic Dermatitis Eczema Skin Diseases Immune System Diseases                                                                                                                                    1\n","Name: count, Length: 12406, dtype: int64"]},"execution_count":9,"metadata":{},"output_type":"execute_result"}],"source":["clin_trials['Medical Subject Headings'].value_counts()"]},{"cell_type":"code","execution_count":10,"id":"4ef0b85c","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:48.834913Z","iopub.status.busy":"2024-06-14T17:30:48.834496Z","iopub.status.idle":"2024-06-14T17:30:54.657612Z","shell.execute_reply":"2024-06-14T17:30:54.656355Z"},"papermill":{"duration":5.844055,"end_time":"2024-06-14T17:30:54.660225","exception":false,"start_time":"2024-06-14T17:30:48.81617","status":"completed"},"tags":[]},"outputs":[],"source":["clin_trials['Start Date'] = clin_trials['Start Date'].apply(parse_mixed_date)\n","clin_trials['Year'] = clin_trials['Start Date'].dt.year\n"]},{"cell_type":"code","execution_count":11,"id":"0dc5f417","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:54.696433Z","iopub.status.busy":"2024-06-14T17:30:54.695444Z","iopub.status.idle":"2024-06-14T17:30:54.700567Z","shell.execute_reply":"2024-06-14T17:30:54.699487Z"},"papermill":{"duration":0.025592,"end_time":"2024-06-14T17:30:54.702703","exception":false,"start_time":"2024-06-14T17:30:54.677111","status":"completed"},"tags":[]},"outputs":[],"source":["categorical_cols = ['Overall Status', 'Primary Purpose', 'Study Type', 'Standard Age', 'Phases', 'Year']"]},{"cell_type":"code","execution_count":12,"id":"b5797495","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:54.73935Z","iopub.status.busy":"2024-06-14T17:30:54.737647Z","iopub.status.idle":"2024-06-14T17:30:54.745611Z","shell.execute_reply":"2024-06-14T17:30:54.744578Z"},"papermill":{"duration":0.028222,"end_time":"2024-06-14T17:30:54.747858","exception":false,"start_time":"2024-06-14T17:30:54.719636","status":"completed"},"tags":[]},"outputs":[{"data":{"text/plain":["['Overall Status',\n"," 'Primary Purpose',\n"," 'Study Type',\n"," 'Standard Age',\n"," 'Phases',\n"," 'Year']"]},"execution_count":12,"metadata":{},"output_type":"execute_result"}],"source":["categorical_cols"]},{"cell_type":"code","execution_count":13,"id":"e17109f1","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:54.784096Z","iopub.status.busy":"2024-06-14T17:30:54.783671Z","iopub.status.idle":"2024-06-14T17:30:54.829044Z","shell.execute_reply":"2024-06-14T17:30:54.827824Z"},"papermill":{"duration":0.065994,"end_time":"2024-06-14T17:30:54.831598","exception":false,"start_time":"2024-06-14T17:30:54.765604","status":"completed"},"tags":[]},"outputs":[{"data":{"text/plain":["Index(['Organization Full Name', 'Brief Title', 'Full Title', 'Overall Status',\n","       'Standard Age', 'Conditions', 'Primary Purpose', 'Interventions',\n","       'Intervention Description', 'Study Type', 'Phases', 'Outcome Measure',\n","       'Year'],\n","      dtype='object')"]},"execution_count":13,"metadata":{},"output_type":"execute_result"}],"source":["clin_trials = clin_trials.drop(['Responsible Party', 'Start Date', 'Organization Class', 'Medical Subject Headings'], axis = 1)\n","clin_trials.columns"]},{"cell_type":"code","execution_count":14,"id":"bb3d28bf","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:54.868488Z","iopub.status.busy":"2024-06-14T17:30:54.868085Z","iopub.status.idle":"2024-06-14T17:30:54.877564Z","shell.execute_reply":"2024-06-14T17:30:54.876565Z"},"papermill":{"duration":0.03057,"end_time":"2024-06-14T17:30:54.879787","exception":false,"start_time":"2024-06-14T17:30:54.849217","status":"completed"},"tags":[]},"outputs":[{"data":{"text/plain":["40"]},"execution_count":14,"metadata":{},"output_type":"execute_result"}],"source":["clin_trials['Year'].nunique()"]},{"cell_type":"code","execution_count":15,"id":"d969340d","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:54.9154Z","iopub.status.busy":"2024-06-14T17:30:54.914998Z","iopub.status.idle":"2024-06-14T17:30:54.922804Z","shell.execute_reply":"2024-06-14T17:30:54.921729Z"},"papermill":{"duration":0.028133,"end_time":"2024-06-14T17:30:54.924932","exception":false,"start_time":"2024-06-14T17:30:54.896799","status":"completed"},"tags":[]},"outputs":[{"data":{"text/plain":["42688"]},"execution_count":15,"metadata":{},"output_type":"execute_result"}],"source":["clin_trials['Year'].isna().sum()"]},{"cell_type":"markdown","id":"943c2c45","metadata":{"papermill":{"duration":0.016742,"end_time":"2024-06-14T17:30:54.958698","exception":false,"start_time":"2024-06-14T17:30:54.941956","status":"completed"},"tags":[]},"source":["# Encoding Relevant Data"]},{"cell_type":"code","execution_count":16,"id":"b922fab9","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:55.054812Z","iopub.status.busy":"2024-06-14T17:30:55.053707Z","iopub.status.idle":"2024-06-14T17:30:55.236894Z","shell.execute_reply":"2024-06-14T17:30:55.235751Z"},"papermill":{"duration":0.263534,"end_time":"2024-06-14T17:30:55.239526","exception":false,"start_time":"2024-06-14T17:30:54.975992","status":"completed"},"tags":[]},"outputs":[],"source":["\n","encoder = OneHotEncoder(sparse=True)\n","\n","# Select only categorical columns for encoding\n","categorical_data = clin_trials[categorical_cols]\n","\n","# Encode categorical columns\n","encoded_trials = encoder.fit_transform(categorical_data)\n","encoded_df = pd.DataFrame.sparse.from_spmatrix(encoded_trials, columns=encoder.get_feature_names_out(categorical_cols))\n"]},{"cell_type":"code","execution_count":17,"id":"f2a5346c","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:55.275665Z","iopub.status.busy":"2024-06-14T17:30:55.275214Z","iopub.status.idle":"2024-06-14T17:30:55.41149Z","shell.execute_reply":"2024-06-14T17:30:55.410053Z"},"papermill":{"duration":0.157875,"end_time":"2024-06-14T17:30:55.414648","exception":false,"start_time":"2024-06-14T17:30:55.256773","status":"completed"},"tags":[]},"outputs":[],"source":["clin_trials_encoded = clin_trials.drop(columns=categorical_cols)\n","\n","# Combine with encoded DataFrame\n","clin_trials = pd.concat([clin_trials_encoded.reset_index(drop=True), encoded_df.reset_index(drop=True)], axis=1)"]},{"cell_type":"code","execution_count":18,"id":"6c18eb70","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:55.45739Z","iopub.status.busy":"2024-06-14T17:30:55.456622Z","iopub.status.idle":"2024-06-14T17:30:55.463772Z","shell.execute_reply":"2024-06-14T17:30:55.462745Z"},"papermill":{"duration":0.03,"end_time":"2024-06-14T17:30:55.466063","exception":false,"start_time":"2024-06-14T17:30:55.436063","status":"completed"},"tags":[]},"outputs":[{"data":{"text/plain":["Index(['Organization Full Name', 'Brief Title', 'Full Title', 'Conditions',\n","       'Interventions', 'Intervention Description', 'Outcome Measure',\n","       'Overall Status_ACTIVE_NOT_RECRUITING',\n","       'Overall Status_APPROVED_FOR_MARKETING', 'Overall Status_AVAILABLE',\n","       'Overall Status_COMPLETED', 'Overall Status_ENROLLING_BY_INVITATION',\n","       'Overall Status_NOT_YET_RECRUITING',\n","       'Overall Status_NO_LONGER_AVAILABLE', 'Overall Status_RECRUITING',\n","       'Overall Status_SUSPENDED', 'Overall Status_TEMPORARILY_NOT_AVAILABLE',\n","       'Overall Status_TERMINATED', 'Overall Status_UNKNOWN',\n","       'Overall Status_WITHDRAWN', 'Primary Purpose_BASIC_SCIENCE',\n","       'Primary Purpose_DEVICE_FEASIBILITY', 'Primary Purpose_DIAGNOSTIC',\n","       'Primary Purpose_HEALTH_SERVICES_RESEARCH', 'Primary Purpose_OTHER',\n","       'Primary Purpose_PREVENTION', 'Primary Purpose_SCREENING',\n","       'Primary Purpose_SUPPORTIVE_CARE', 'Primary Purpose_TREATMENT',\n","       'Primary Purpose_Unknown', 'Study Type_EXPANDED_ACCESS',\n","       'Study Type_INTERVENTIONAL', 'Study Type_OBSERVATIONAL',\n","       'Standard Age_ADULT', 'Standard Age_ADULT OLDER_ADULT',\n","       'Standard Age_CHILD', 'Standard Age_CHILD ADULT',\n","       'Standard Age_CHILD ADULT OLDER_ADULT', 'Standard Age_OLDER_ADULT',\n","       'Phases_EARLY_PHASE1', 'Phases_PHASE1', 'Phases_PHASE1, PHASE2',\n","       'Phases_PHASE2', 'Phases_PHASE2, PHASE3', 'Phases_PHASE3',\n","       'Phases_PHASE4', 'Phases_Unknown', 'Phases_nan', 'Year_1916.0',\n","       'Year_1987.0', 'Year_1990.0', 'Year_1991.0', 'Year_1992.0',\n","       'Year_1993.0', 'Year_1994.0', 'Year_1995.0', 'Year_1996.0',\n","       'Year_1997.0', 'Year_1998.0', 'Year_1999.0', 'Year_2000.0',\n","       'Year_2001.0', 'Year_2002.0', 'Year_2003.0', 'Year_2004.0',\n","       'Year_2005.0', 'Year_2006.0', 'Year_2007.0', 'Year_2008.0',\n","       'Year_2009.0', 'Year_2010.0', 'Year_2011.0', 'Year_2012.0',\n","       'Year_2013.0', 'Year_2014.0', 'Year_2015.0', 'Year_2016.0',\n","       'Year_2017.0', 'Year_2018.0', 'Year_2019.0', 'Year_2020.0',\n","       'Year_2021.0', 'Year_2022.0', 'Year_2023.0', 'Year_2024.0',\n","       'Year_2025.0', 'Year_2026.0', 'Year_2030.0', 'Year_nan'],\n","      dtype='object')"]},"execution_count":18,"metadata":{},"output_type":"execute_result"}],"source":["clin_trials.columns"]},{"cell_type":"code","execution_count":19,"id":"73b98205","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:55.503343Z","iopub.status.busy":"2024-06-14T17:30:55.502304Z","iopub.status.idle":"2024-06-14T17:30:55.529677Z","shell.execute_reply":"2024-06-14T17:30:55.528605Z"},"papermill":{"duration":0.048322,"end_time":"2024-06-14T17:30:55.532014","exception":false,"start_time":"2024-06-14T17:30:55.483692","status":"completed"},"tags":[]},"outputs":[{"data":{"text/plain":["Organization Full Name\n","GlaxoSmithKline               3374\n","Pfizer                        2772\n","Novartis                      2772\n","AstraZeneca                   2224\n","Boehringer Ingelheim          1914\n","                              ... \n","Paragate Medical LTD             1\n","Kendal Nutricare Ltd             1\n","Oxford BioTherapeutics Ltd       1\n","Kinarus AG                       1\n","Crestone, Inc                    1\n","Name: count, Length: 11732, dtype: int64"]},"execution_count":19,"metadata":{},"output_type":"execute_result"}],"source":["clin_trials['Organization Full Name'].value_counts()"]},{"cell_type":"markdown","id":"13ce6b36","metadata":{"papermill":{"duration":0.016986,"end_time":"2024-06-14T17:30:55.566358","exception":false,"start_time":"2024-06-14T17:30:55.549372","status":"completed"},"tags":[]},"source":["# Calculating Studies per Company"]},{"cell_type":"code","execution_count":20,"id":"840af5e6","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:55.603431Z","iopub.status.busy":"2024-06-14T17:30:55.603006Z","iopub.status.idle":"2024-06-14T17:30:55.625614Z","shell.execute_reply":"2024-06-14T17:30:55.624613Z"},"papermill":{"duration":0.044234,"end_time":"2024-06-14T17:30:55.627962","exception":false,"start_time":"2024-06-14T17:30:55.583728","status":"completed"},"tags":[]},"outputs":[],"source":["entry_count_df = clin_trials['Organization Full Name'].value_counts().reset_index()\n","entry_count_df.columns = ['Organization Full Name', 'entry_count']"]},{"cell_type":"code","execution_count":21,"id":"26465b03","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:55.664868Z","iopub.status.busy":"2024-06-14T17:30:55.664459Z","iopub.status.idle":"2024-06-14T17:30:55.674809Z","shell.execute_reply":"2024-06-14T17:30:55.673746Z"},"papermill":{"duration":0.031315,"end_time":"2024-06-14T17:30:55.677133","exception":false,"start_time":"2024-06-14T17:30:55.645818","status":"completed"},"tags":[]},"outputs":[{"data":{"text/html":["<div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>Organization Full Name</th>\n","      <th>entry_count</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <th>0</th>\n","      <td>GlaxoSmithKline</td>\n","      <td>3374</td>\n","    </tr>\n","    <tr>\n","      <th>1</th>\n","      <td>Pfizer</td>\n","      <td>2772</td>\n","    </tr>\n","    <tr>\n","      <th>2</th>\n","      <td>Novartis</td>\n","      <td>2772</td>\n","    </tr>\n","    <tr>\n","      <th>3</th>\n","      <td>AstraZeneca</td>\n","      <td>2224</td>\n","    </tr>\n","    <tr>\n","      <th>4</th>\n","      <td>Boehringer Ingelheim</td>\n","      <td>1914</td>\n","    </tr>\n","  </tbody>\n","</table>\n","</div>"],"text/plain":["  Organization Full Name  entry_count\n","0        GlaxoSmithKline         3374\n","1                 Pfizer         2772\n","2               Novartis         2772\n","3            AstraZeneca         2224\n","4   Boehringer Ingelheim         1914"]},"execution_count":21,"metadata":{},"output_type":"execute_result"}],"source":["entry_count_df.head()"]},{"cell_type":"code","execution_count":22,"id":"a47f1735","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:55.715187Z","iopub.status.busy":"2024-06-14T17:30:55.71439Z","iopub.status.idle":"2024-06-14T17:30:55.789701Z","shell.execute_reply":"2024-06-14T17:30:55.788493Z"},"papermill":{"duration":0.096999,"end_time":"2024-06-14T17:30:55.792209","exception":false,"start_time":"2024-06-14T17:30:55.69521","status":"completed"},"tags":[]},"outputs":[],"source":["clin_trials = clin_trials.merge(entry_count_df, on='Organization Full Name', how='left')"]},{"cell_type":"code","execution_count":23,"id":"3629e284","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:55.83072Z","iopub.status.busy":"2024-06-14T17:30:55.829553Z","iopub.status.idle":"2024-06-14T17:30:55.837495Z","shell.execute_reply":"2024-06-14T17:30:55.836321Z"},"papermill":{"duration":0.0293,"end_time":"2024-06-14T17:30:55.839787","exception":false,"start_time":"2024-06-14T17:30:55.810487","status":"completed"},"tags":[]},"outputs":[{"data":{"text/plain":["Index(['Organization Full Name', 'Brief Title', 'Full Title', 'Conditions',\n","       'Interventions', 'Intervention Description', 'Outcome Measure',\n","       'Overall Status_ACTIVE_NOT_RECRUITING',\n","       'Overall Status_APPROVED_FOR_MARKETING', 'Overall Status_AVAILABLE',\n","       'Overall Status_COMPLETED', 'Overall Status_ENROLLING_BY_INVITATION',\n","       'Overall Status_NOT_YET_RECRUITING',\n","       'Overall Status_NO_LONGER_AVAILABLE', 'Overall Status_RECRUITING',\n","       'Overall Status_SUSPENDED', 'Overall Status_TEMPORARILY_NOT_AVAILABLE',\n","       'Overall Status_TERMINATED', 'Overall Status_UNKNOWN',\n","       'Overall Status_WITHDRAWN', 'Primary Purpose_BASIC_SCIENCE',\n","       'Primary Purpose_DEVICE_FEASIBILITY', 'Primary Purpose_DIAGNOSTIC',\n","       'Primary Purpose_HEALTH_SERVICES_RESEARCH', 'Primary Purpose_OTHER',\n","       'Primary Purpose_PREVENTION', 'Primary Purpose_SCREENING',\n","       'Primary Purpose_SUPPORTIVE_CARE', 'Primary Purpose_TREATMENT',\n","       'Primary Purpose_Unknown', 'Study Type_EXPANDED_ACCESS',\n","       'Study Type_INTERVENTIONAL', 'Study Type_OBSERVATIONAL',\n","       'Standard Age_ADULT', 'Standard Age_ADULT OLDER_ADULT',\n","       'Standard Age_CHILD', 'Standard Age_CHILD ADULT',\n","       'Standard Age_CHILD ADULT OLDER_ADULT', 'Standard Age_OLDER_ADULT',\n","       'Phases_EARLY_PHASE1', 'Phases_PHASE1', 'Phases_PHASE1, PHASE2',\n","       'Phases_PHASE2', 'Phases_PHASE2, PHASE3', 'Phases_PHASE3',\n","       'Phases_PHASE4', 'Phases_Unknown', 'Phases_nan', 'Year_1916.0',\n","       'Year_1987.0', 'Year_1990.0', 'Year_1991.0', 'Year_1992.0',\n","       'Year_1993.0', 'Year_1994.0', 'Year_1995.0', 'Year_1996.0',\n","       'Year_1997.0', 'Year_1998.0', 'Year_1999.0', 'Year_2000.0',\n","       'Year_2001.0', 'Year_2002.0', 'Year_2003.0', 'Year_2004.0',\n","       'Year_2005.0', 'Year_2006.0', 'Year_2007.0', 'Year_2008.0',\n","       'Year_2009.0', 'Year_2010.0', 'Year_2011.0', 'Year_2012.0',\n","       'Year_2013.0', 'Year_2014.0', 'Year_2015.0', 'Year_2016.0',\n","       'Year_2017.0', 'Year_2018.0', 'Year_2019.0', 'Year_2020.0',\n","       'Year_2021.0', 'Year_2022.0', 'Year_2023.0', 'Year_2024.0',\n","       'Year_2025.0', 'Year_2026.0', 'Year_2030.0', 'Year_nan', 'entry_count'],\n","      dtype='object')"]},"execution_count":23,"metadata":{},"output_type":"execute_result"}],"source":["clin_trials.columns"]},{"cell_type":"markdown","id":"12f235f6","metadata":{"papermill":{"duration":0.017566,"end_time":"2024-06-14T17:30:55.875845","exception":false,"start_time":"2024-06-14T17:30:55.858279","status":"completed"},"tags":[]},"source":["# Combining titles and interventions "]},{"cell_type":"code","execution_count":24,"id":"3a05224d","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:55.913781Z","iopub.status.busy":"2024-06-14T17:30:55.912699Z","iopub.status.idle":"2024-06-14T17:30:55.917754Z","shell.execute_reply":"2024-06-14T17:30:55.916731Z"},"id":"CwO4y4MBWC1j","papermill":{"duration":0.026173,"end_time":"2024-06-14T17:30:55.919932","exception":false,"start_time":"2024-06-14T17:30:55.893759","status":"completed"},"tags":[]},"outputs":[],"source":["combined_titles_cols = ['Brief Title', 'Full Title', 'Conditions']\n","combined_inter_cols = ['Interventions', 'Intervention Description']\n"]},{"cell_type":"code","execution_count":25,"id":"48d8c999","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:55.957055Z","iopub.status.busy":"2024-06-14T17:30:55.956682Z","iopub.status.idle":"2024-06-14T17:30:55.9623Z","shell.execute_reply":"2024-06-14T17:30:55.961143Z"},"id":"newuvpJ2ZS95","papermill":{"duration":0.02677,"end_time":"2024-06-14T17:30:55.964348","exception":false,"start_time":"2024-06-14T17:30:55.937578","status":"completed"},"tags":[]},"outputs":[],"source":["def concat(columns):\n","    '''Combines text columns into a single column in place\n","    Parameter: List of text columns to be joined\n","    Returns: None (changes are done in place)'''\n","    cols = [col for col in columns]\n","    clin_trials['combined_text'] = clin_trials[cols].agg(' '.join, axis=1)\n","    clin_trials.columns"]},{"cell_type":"code","execution_count":26,"id":"c4303392","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:56.014015Z","iopub.status.busy":"2024-06-14T17:30:56.013614Z","iopub.status.idle":"2024-06-14T17:30:56.716403Z","shell.execute_reply":"2024-06-14T17:30:56.715346Z"},"papermill":{"duration":0.736911,"end_time":"2024-06-14T17:30:56.718956","exception":false,"start_time":"2024-06-14T17:30:55.982045","status":"completed"},"tags":[]},"outputs":[],"source":["concat(combined_titles_cols)"]},{"cell_type":"code","execution_count":27,"id":"34c7453f","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:56.756097Z","iopub.status.busy":"2024-06-14T17:30:56.755724Z","iopub.status.idle":"2024-06-14T17:30:56.795609Z","shell.execute_reply":"2024-06-14T17:30:56.794666Z"},"papermill":{"duration":0.061412,"end_time":"2024-06-14T17:30:56.798109","exception":false,"start_time":"2024-06-14T17:30:56.736697","status":"completed"},"tags":[]},"outputs":[],"source":["clin_trials['combined_titles'] = clin_trials['combined_text']\n","clin_trials = clin_trials.drop(columns = ['combined_text'])"]},{"cell_type":"code","execution_count":28,"id":"13b8bf42","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:56.834936Z","iopub.status.busy":"2024-06-14T17:30:56.834556Z","iopub.status.idle":"2024-06-14T17:30:57.478304Z","shell.execute_reply":"2024-06-14T17:30:57.477277Z"},"papermill":{"duration":0.665045,"end_time":"2024-06-14T17:30:57.480793","exception":false,"start_time":"2024-06-14T17:30:56.815748","status":"completed"},"tags":[]},"outputs":[],"source":["concat(combined_inter_cols)\n"]},{"cell_type":"code","execution_count":29,"id":"fb4e3b8b","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:57.517906Z","iopub.status.busy":"2024-06-14T17:30:57.517496Z","iopub.status.idle":"2024-06-14T17:30:57.560682Z","shell.execute_reply":"2024-06-14T17:30:57.559685Z"},"papermill":{"duration":0.064558,"end_time":"2024-06-14T17:30:57.563122","exception":false,"start_time":"2024-06-14T17:30:57.498564","status":"completed"},"tags":[]},"outputs":[],"source":["clin_trials['Intervention Desc'] = clin_trials['combined_text']\n","clin_trials = clin_trials.drop(columns = 'combined_text')\n"]},{"cell_type":"code","execution_count":30,"id":"452604f7","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:57.600658Z","iopub.status.busy":"2024-06-14T17:30:57.59983Z","iopub.status.idle":"2024-06-14T17:30:57.63254Z","shell.execute_reply":"2024-06-14T17:30:57.631521Z"},"papermill":{"duration":0.053948,"end_time":"2024-06-14T17:30:57.634731","exception":false,"start_time":"2024-06-14T17:30:57.580783","status":"completed"},"tags":[]},"outputs":[{"data":{"text/plain":["Index(['Organization Full Name', 'Outcome Measure',\n","       'Overall Status_ACTIVE_NOT_RECRUITING',\n","       'Overall Status_APPROVED_FOR_MARKETING', 'Overall Status_AVAILABLE',\n","       'Overall Status_COMPLETED', 'Overall Status_ENROLLING_BY_INVITATION',\n","       'Overall Status_NOT_YET_RECRUITING',\n","       'Overall Status_NO_LONGER_AVAILABLE', 'Overall Status_RECRUITING',\n","       'Overall Status_SUSPENDED', 'Overall Status_TEMPORARILY_NOT_AVAILABLE',\n","       'Overall Status_TERMINATED', 'Overall Status_UNKNOWN',\n","       'Overall Status_WITHDRAWN', 'Primary Purpose_BASIC_SCIENCE',\n","       'Primary Purpose_DEVICE_FEASIBILITY', 'Primary Purpose_DIAGNOSTIC',\n","       'Primary Purpose_HEALTH_SERVICES_RESEARCH', 'Primary Purpose_OTHER',\n","       'Primary Purpose_PREVENTION', 'Primary Purpose_SCREENING',\n","       'Primary Purpose_SUPPORTIVE_CARE', 'Primary Purpose_TREATMENT',\n","       'Primary Purpose_Unknown', 'Study Type_EXPANDED_ACCESS',\n","       'Study Type_INTERVENTIONAL', 'Study Type_OBSERVATIONAL',\n","       'Standard Age_ADULT', 'Standard Age_ADULT OLDER_ADULT',\n","       'Standard Age_CHILD', 'Standard Age_CHILD ADULT',\n","       'Standard Age_CHILD ADULT OLDER_ADULT', 'Standard Age_OLDER_ADULT',\n","       'Phases_EARLY_PHASE1', 'Phases_PHASE1', 'Phases_PHASE1, PHASE2',\n","       'Phases_PHASE2', 'Phases_PHASE2, PHASE3', 'Phases_PHASE3',\n","       'Phases_PHASE4', 'Phases_Unknown', 'Phases_nan', 'Year_1916.0',\n","       'Year_1987.0', 'Year_1990.0', 'Year_1991.0', 'Year_1992.0',\n","       'Year_1993.0', 'Year_1994.0', 'Year_1995.0', 'Year_1996.0',\n","       'Year_1997.0', 'Year_1998.0', 'Year_1999.0', 'Year_2000.0',\n","       'Year_2001.0', 'Year_2002.0', 'Year_2003.0', 'Year_2004.0',\n","       'Year_2005.0', 'Year_2006.0', 'Year_2007.0', 'Year_2008.0',\n","       'Year_2009.0', 'Year_2010.0', 'Year_2011.0', 'Year_2012.0',\n","       'Year_2013.0', 'Year_2014.0', 'Year_2015.0', 'Year_2016.0',\n","       'Year_2017.0', 'Year_2018.0', 'Year_2019.0', 'Year_2020.0',\n","       'Year_2021.0', 'Year_2022.0', 'Year_2023.0', 'Year_2024.0',\n","       'Year_2025.0', 'Year_2026.0', 'Year_2030.0', 'Year_nan', 'entry_count',\n","       'combined_titles', 'Intervention Desc'],\n","      dtype='object')"]},"execution_count":30,"metadata":{},"output_type":"execute_result"}],"source":["clin_trials = clin_trials.drop(columns = ['Brief Title', 'Full Title', 'Conditions','Interventions', 'Intervention Description'])\n","clin_trials.columns"]},{"cell_type":"markdown","id":"50e44efc","metadata":{"papermill":{"duration":0.018181,"end_time":"2024-06-14T17:30:57.671466","exception":false,"start_time":"2024-06-14T17:30:57.653285","status":"completed"},"tags":[]},"source":["# Preprocessing Text for Vectorization"]},{"cell_type":"code","execution_count":31,"id":"91545cb3","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:57.708715Z","iopub.status.busy":"2024-06-14T17:30:57.708279Z","iopub.status.idle":"2024-06-14T17:30:57.714975Z","shell.execute_reply":"2024-06-14T17:30:57.713948Z"},"id":"WDUnjc4ELaby","papermill":{"duration":0.028028,"end_time":"2024-06-14T17:30:57.717351","exception":false,"start_time":"2024-06-14T17:30:57.689323","status":"completed"},"tags":[]},"outputs":[],"source":["def preprocess_text(text):\n","    '''Preprocesses text as preparation for vectorization\n","    Parameter: A string of text\n","    Returns: lemmatized text'''\n","    # Remove punctuation including '|'\n","    text = text.translate(str.maketrans('', '', string.punctuation + '|')).lower()\n","    # Tokenize\n","    tokens = word_tokenize(text)\n","    # Remove stopwords\n","    tokens = [word for word in tokens if word not in stopwords.words('english')]\n","    # Lemmatize\n","    lemmatizer = WordNetLemmatizer()\n","    tokens = [lemmatizer.lemmatize(word) for word in tokens]\n","    return ' '.join(tokens)"]},{"cell_type":"code","execution_count":32,"id":"9013e523","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:30:57.755275Z","iopub.status.busy":"2024-06-14T17:30:57.754881Z","iopub.status.idle":"2024-06-14T17:39:57.328369Z","shell.execute_reply":"2024-06-14T17:39:57.327006Z"},"id":"a708GAEH7SsT","papermill":{"duration":539.596133,"end_time":"2024-06-14T17:39:57.331893","exception":false,"start_time":"2024-06-14T17:30:57.73576","status":"completed"},"tags":[]},"outputs":[],"source":["clin_trials['combined_titles'] = clin_trials['combined_titles'].apply(preprocess_text)\n"]},{"cell_type":"code","execution_count":33,"id":"44a0278b","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:39:57.370774Z","iopub.status.busy":"2024-06-14T17:39:57.370339Z","iopub.status.idle":"2024-06-14T17:47:15.708803Z","shell.execute_reply":"2024-06-14T17:47:15.707474Z"},"papermill":{"duration":438.360918,"end_time":"2024-06-14T17:47:15.711972","exception":false,"start_time":"2024-06-14T17:39:57.351054","status":"completed"},"tags":[]},"outputs":[],"source":["clin_trials['Intervention Desc'] = clin_trials['Intervention Desc'].apply(preprocess_text)"]},{"cell_type":"code","execution_count":34,"id":"5603a015","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:47:15.750325Z","iopub.status.busy":"2024-06-14T17:47:15.749916Z","iopub.status.idle":"2024-06-14T17:52:49.809923Z","shell.execute_reply":"2024-06-14T17:52:49.808701Z"},"papermill":{"duration":334.08267,"end_time":"2024-06-14T17:52:49.81283","exception":false,"start_time":"2024-06-14T17:47:15.73016","status":"completed"},"tags":[]},"outputs":[],"source":["clin_trials['Outcome Measure'] = clin_trials['Outcome Measure'].apply(preprocess_text)"]},{"cell_type":"code","execution_count":35,"id":"adc509fa","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:52:49.851175Z","iopub.status.busy":"2024-06-14T17:52:49.850752Z","iopub.status.idle":"2024-06-14T17:52:49.85625Z","shell.execute_reply":"2024-06-14T17:52:49.854978Z"},"id":"HnSL-io5glwG","papermill":{"duration":0.027676,"end_time":"2024-06-14T17:52:49.858674","exception":false,"start_time":"2024-06-14T17:52:49.830998","status":"completed"},"tags":[]},"outputs":[],"source":["vectorizer = TfidfVectorizer(min_df = .01, max_df = .9)"]},{"cell_type":"code","execution_count":36,"id":"842a901b","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:52:49.897368Z","iopub.status.busy":"2024-06-14T17:52:49.896964Z","iopub.status.idle":"2024-06-14T17:52:52.814063Z","shell.execute_reply":"2024-06-14T17:52:52.81285Z"},"id":"PSC-NLquhcMv","papermill":{"duration":2.939453,"end_time":"2024-06-14T17:52:52.816761","exception":false,"start_time":"2024-06-14T17:52:49.877308","status":"completed"},"tags":[]},"outputs":[],"source":["vec_title = vectorizer.fit_transform(clin_trials['combined_titles'])"]},{"cell_type":"code","execution_count":37,"id":"e81dad15","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:52:52.855526Z","iopub.status.busy":"2024-06-14T17:52:52.855143Z","iopub.status.idle":"2024-06-14T17:52:52.878486Z","shell.execute_reply":"2024-06-14T17:52:52.877229Z"},"papermill":{"duration":0.04635,"end_time":"2024-06-14T17:52:52.88112","exception":false,"start_time":"2024-06-14T17:52:52.83477","status":"completed"},"tags":[]},"outputs":[],"source":["vec_title_df = pd.DataFrame.sparse.from_spmatrix(vec_title, columns=vectorizer.get_feature_names_out())"]},{"cell_type":"code","execution_count":38,"id":"90fc3a56","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:52:52.918805Z","iopub.status.busy":"2024-06-14T17:52:52.918392Z","iopub.status.idle":"2024-06-14T17:52:55.281636Z","shell.execute_reply":"2024-06-14T17:52:55.280471Z"},"papermill":{"duration":2.384935,"end_time":"2024-06-14T17:52:55.284206","exception":false,"start_time":"2024-06-14T17:52:52.899271","status":"completed"},"tags":[]},"outputs":[],"source":["vec_intervention = vectorizer.fit_transform(clin_trials['Intervention Desc'])"]},{"cell_type":"code","execution_count":39,"id":"a5812081","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:52:55.321982Z","iopub.status.busy":"2024-06-14T17:52:55.321575Z","iopub.status.idle":"2024-06-14T17:52:55.337118Z","shell.execute_reply":"2024-06-14T17:52:55.336026Z"},"papermill":{"duration":0.037351,"end_time":"2024-06-14T17:52:55.339761","exception":false,"start_time":"2024-06-14T17:52:55.30241","status":"completed"},"tags":[]},"outputs":[],"source":["vec_intervention_df = pd.DataFrame.sparse.from_spmatrix(vec_intervention, columns = vectorizer.get_feature_names_out())"]},{"cell_type":"code","execution_count":40,"id":"07ca2ea4","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:52:55.381962Z","iopub.status.busy":"2024-06-14T17:52:55.381423Z","iopub.status.idle":"2024-06-14T17:52:57.148581Z","shell.execute_reply":"2024-06-14T17:52:57.147526Z"},"papermill":{"duration":1.793532,"end_time":"2024-06-14T17:52:57.151222","exception":false,"start_time":"2024-06-14T17:52:55.35769","status":"completed"},"tags":[]},"outputs":[],"source":["vec_outcome = vectorizer.fit_transform(clin_trials['Outcome Measure'])"]},{"cell_type":"code","execution_count":41,"id":"de402ee0","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:52:57.188429Z","iopub.status.busy":"2024-06-14T17:52:57.188036Z","iopub.status.idle":"2024-06-14T17:52:57.203875Z","shell.execute_reply":"2024-06-14T17:52:57.202808Z"},"papermill":{"duration":0.037294,"end_time":"2024-06-14T17:52:57.206418","exception":false,"start_time":"2024-06-14T17:52:57.169124","status":"completed"},"tags":[]},"outputs":[],"source":["vec_outcome_df = pd.DataFrame.sparse.from_spmatrix(vec_outcome, columns = vectorizer.get_feature_names_out())"]},{"cell_type":"markdown","id":"485c44c6","metadata":{"papermill":{"duration":0.017503,"end_time":"2024-06-14T17:52:57.242008","exception":false,"start_time":"2024-06-14T17:52:57.224505","status":"completed"},"tags":[]},"source":["# Scaling Data"]},{"cell_type":"code","execution_count":42,"id":"f0368ab8","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:52:57.279062Z","iopub.status.busy":"2024-06-14T17:52:57.278659Z","iopub.status.idle":"2024-06-14T17:52:57.798125Z","shell.execute_reply":"2024-06-14T17:52:57.797207Z"},"papermill":{"duration":0.540934,"end_time":"2024-06-14T17:52:57.800693","exception":false,"start_time":"2024-06-14T17:52:57.259759","status":"completed"},"tags":[]},"outputs":[],"source":["non_sparse_cols = ['entry_count']\n","sparse_scaler = MaxAbsScaler()\n","title_sparse = sparse_scaler.fit_transform(vec_title_df)\n","intervention_sparse = sparse_scaler.fit_transform(vec_intervention_df)\n","outcome_sparse = sparse_scaler.fit_transform(vec_outcome_df)\n","non_sparse_scaler = StandardScaler()\n","scaled_non_sparse_data = non_sparse_scaler.fit_transform(clin_trials[non_sparse_cols])\n","\n"]},{"cell_type":"code","execution_count":43,"id":"ed6f682d","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:52:57.838769Z","iopub.status.busy":"2024-06-14T17:52:57.837969Z","iopub.status.idle":"2024-06-14T17:52:57.886109Z","shell.execute_reply":"2024-06-14T17:52:57.885042Z"},"papermill":{"duration":0.07005,"end_time":"2024-06-14T17:52:57.888589","exception":false,"start_time":"2024-06-14T17:52:57.818539","status":"completed"},"tags":[]},"outputs":[],"source":["title_sparse_df = pd.DataFrame.sparse.from_spmatrix(title_sparse, columns=vec_title_df.columns)\n","intervention_sparse_df = pd.DataFrame.sparse.from_spmatrix(intervention_sparse, columns=vec_intervention_df.columns)\n","outcome_sparse_df = pd.DataFrame.sparse.from_spmatrix(outcome_sparse, columns=vec_outcome_df.columns)\n","scaled_non_sparse_df = pd.DataFrame(scaled_non_sparse_data, columns=non_sparse_cols)\n"]},{"cell_type":"code","execution_count":44,"id":"276a0e58","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:52:57.926717Z","iopub.status.busy":"2024-06-14T17:52:57.925571Z","iopub.status.idle":"2024-06-14T17:52:57.935443Z","shell.execute_reply":"2024-06-14T17:52:57.934394Z"},"papermill":{"duration":0.031254,"end_time":"2024-06-14T17:52:57.937853","exception":false,"start_time":"2024-06-14T17:52:57.906599","status":"completed"},"tags":[]},"outputs":[],"source":["concatenated_columns = (\n","    list(clin_trials[['Organization Full Name']].columns) +\n","    list(title_sparse_df.columns) +  \n","    list(intervention_sparse_df.columns) + \n","    list(outcome_sparse_df.columns) + \n","    list(encoded_df.columns) +\n","    list(scaled_non_sparse_df.columns) # entry_count should be here\n",")"]},{"cell_type":"code","execution_count":45,"id":"52071cef","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:52:57.975048Z","iopub.status.busy":"2024-06-14T17:52:57.974624Z","iopub.status.idle":"2024-06-14T17:52:58.121663Z","shell.execute_reply":"2024-06-14T17:52:58.120455Z"},"papermill":{"duration":0.168798,"end_time":"2024-06-14T17:52:58.124415","exception":false,"start_time":"2024-06-14T17:52:57.955617","status":"completed"},"tags":[]},"outputs":[],"source":["clin_trials = pd.concat([\n","    clin_trials[['Organization Full Name']].reset_index(drop=True),\n","    title_sparse_df.reset_index(drop=True),\n","    intervention_sparse_df.reset_index(drop=True),\n","    outcome_sparse_df.reset_index(drop=True),\n","    scaled_non_sparse_df.reset_index(drop=True),\n","    encoded_df.reset_index(drop=True),\n","], axis=1, ignore_index=True)\n","clin_trials.columns = concatenated_columns"]},{"cell_type":"markdown","id":"07e8c3f2","metadata":{"papermill":{"duration":0.017675,"end_time":"2024-06-14T17:52:58.160657","exception":false,"start_time":"2024-06-14T17:52:58.142982","status":"completed"},"tags":[]},"source":["# Resolving duplicate column names as a result of vectorization. "]},{"cell_type":"code","execution_count":46,"id":"9b620491","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:52:58.197721Z","iopub.status.busy":"2024-06-14T17:52:58.19729Z","iopub.status.idle":"2024-06-14T17:52:58.204299Z","shell.execute_reply":"2024-06-14T17:52:58.203069Z"},"papermill":{"duration":0.028303,"end_time":"2024-06-14T17:52:58.206503","exception":false,"start_time":"2024-06-14T17:52:58.1782","status":"completed"},"tags":[]},"outputs":[],"source":["def resolve_duplicate_columns(df):\n","    \"\"\"\n","    Resolve duplicate column names in a DataFrame by appending _[i] to duplicate columns.\n","\n","    Parameters:\n","    df (pandas.DataFrame): Input DataFrame.\n","\n","    Returns:\n","    pandas.DataFrame: DataFrame with unique column names.\n","    \"\"\"\n","    seen = {}\n","    new_columns = []\n","    for column in df.columns:\n","        if column in seen:\n","            seen[column] += 1\n","            new_columns.append(f\"{column}_{seen[column]}\")\n","        else:\n","            seen[column] = 1\n","            new_columns.append(column)\n","    df.columns = new_columns\n","    return df"]},{"cell_type":"code","execution_count":47,"id":"9a0b1b7d","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:52:58.243852Z","iopub.status.busy":"2024-06-14T17:52:58.243427Z","iopub.status.idle":"2024-06-14T17:52:58.249164Z","shell.execute_reply":"2024-06-14T17:52:58.248125Z"},"papermill":{"duration":0.027169,"end_time":"2024-06-14T17:52:58.251423","exception":false,"start_time":"2024-06-14T17:52:58.224254","status":"completed"},"tags":[]},"outputs":[],"source":["clin_trials = resolve_duplicate_columns(clin_trials)"]},{"cell_type":"code","execution_count":48,"id":"e9cc186a","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:52:58.28953Z","iopub.status.busy":"2024-06-14T17:52:58.288619Z","iopub.status.idle":"2024-06-14T17:52:58.295579Z","shell.execute_reply":"2024-06-14T17:52:58.294504Z"},"papermill":{"duration":0.028603,"end_time":"2024-06-14T17:52:58.29784","exception":false,"start_time":"2024-06-14T17:52:58.269237","status":"completed"},"tags":[]},"outputs":[{"data":{"text/plain":["700"]},"execution_count":48,"metadata":{},"output_type":"execute_result"}],"source":["len(clin_trials.columns)"]},{"cell_type":"code","execution_count":49,"id":"03a0c848","metadata":{"execution":{"iopub.execute_input":"2024-06-14T17:52:58.334999Z","iopub.status.busy":"2024-06-14T17:52:58.334632Z","iopub.status.idle":"2024-06-14T18:09:02.000275Z","shell.execute_reply":"2024-06-14T18:09:01.998806Z"},"papermill":{"duration":963.687603,"end_time":"2024-06-14T18:09:02.003232","exception":false,"start_time":"2024-06-14T17:52:58.315629","status":"completed"},"tags":[]},"outputs":[],"source":["clin_trials_grouped = clin_trials.groupby('Organization Full Name').mean().reset_index()\n","    "]},{"cell_type":"markdown","id":"0c44d104","metadata":{"papermill":{"duration":0.017608,"end_time":"2024-06-14T18:09:02.040204","exception":false,"start_time":"2024-06-14T18:09:02.022596","status":"completed"},"tags":[]},"source":["# Separating out the 'Organization Full Name' for Dimensionality Reduction"]},{"cell_type":"code","execution_count":50,"id":"c76b511a","metadata":{"execution":{"iopub.execute_input":"2024-06-14T18:09:02.077992Z","iopub.status.busy":"2024-06-14T18:09:02.077586Z","iopub.status.idle":"2024-06-14T18:09:02.252833Z","shell.execute_reply":"2024-06-14T18:09:02.2517Z"},"papermill":{"duration":0.19719,"end_time":"2024-06-14T18:09:02.255409","exception":false,"start_time":"2024-06-14T18:09:02.058219","status":"completed"},"tags":[]},"outputs":[],"source":["X = clin_trials_grouped.drop(columns=['Organization Full Name'])\n","y = clin_trials_grouped['Organization Full Name']"]},{"cell_type":"code","execution_count":51,"id":"b7128f0a","metadata":{"execution":{"iopub.execute_input":"2024-06-14T18:09:02.293378Z","iopub.status.busy":"2024-06-14T18:09:02.292994Z","iopub.status.idle":"2024-06-14T18:09:02.298261Z","shell.execute_reply":"2024-06-14T18:09:02.297179Z"},"papermill":{"duration":0.02671,"end_time":"2024-06-14T18:09:02.300498","exception":false,"start_time":"2024-06-14T18:09:02.273788","status":"completed"},"tags":[]},"outputs":[],"source":["n_components_list = [2, 5, 10, 20, 50, 100, 200, 300, 400]"]},{"cell_type":"code","execution_count":52,"id":"366dfdbc","metadata":{"execution":{"iopub.execute_input":"2024-06-14T18:09:02.341174Z","iopub.status.busy":"2024-06-14T18:09:02.340494Z","iopub.status.idle":"2024-06-14T18:09:18.964546Z","shell.execute_reply":"2024-06-14T18:09:18.963495Z"},"papermill":{"duration":16.647762,"end_time":"2024-06-14T18:09:18.967851","exception":false,"start_time":"2024-06-14T18:09:02.320089","status":"completed"},"tags":[]},"outputs":[{"name":"stdout","output_type":"stream","text":["n_components=2: Total explained variance=0.1375\n","n_components=5: Total explained variance=0.3081\n","n_components=10: Total explained variance=0.4262\n","n_components=20: Total explained variance=0.5384\n","n_components=50: Total explained variance=0.6667\n","n_components=100: Total explained variance=0.7547\n","n_components=200: Total explained variance=0.8552\n","n_components=300: Total explained variance=0.9140\n","n_components=400: Total explained variance=0.9523\n"]}],"source":["explained_variance_results = {}\n","\n","for n in n_components_list:\n","    # Apply TruncatedSVD\n","    svd = TruncatedSVD(n_components=n, random_state=42)\n","    X_reduced = svd.fit_transform(X)\n","\n","    # Calculate explained variance ratio\n","    explained_variance = svd.explained_variance_ratio_\n","    total_explained_variance = explained_variance.sum()\n","\n","    # Store the results\n","    explained_variance_results[n] = total_explained_variance\n","\n","# Print the results\n","for n, variance in explained_variance_results.items():\n","    print(f\"n_components={n}: Total explained variance={variance:.4f}\")"]},{"cell_type":"markdown","id":"9e779e7b","metadata":{"papermill":{"duration":0.022818,"end_time":"2024-06-14T18:09:19.020861","exception":false,"start_time":"2024-06-14T18:09:18.998043","status":"completed"},"tags":[]},"source":["# Using 400 components to get 95% of the variation. "]},{"cell_type":"code","execution_count":53,"id":"dba9884d","metadata":{"execution":{"iopub.execute_input":"2024-06-14T18:09:19.05923Z","iopub.status.busy":"2024-06-14T18:09:19.058747Z","iopub.status.idle":"2024-06-14T18:09:23.215369Z","shell.execute_reply":"2024-06-14T18:09:23.214119Z"},"papermill":{"duration":4.178738,"end_time":"2024-06-14T18:09:23.217856","exception":false,"start_time":"2024-06-14T18:09:19.039118","status":"completed"},"tags":[]},"outputs":[],"source":["calc_svd = TruncatedSVD(n_components = 400, random_state=42)\n","calc_X = calc_svd.fit_transform(X)\n","clin_trials_calc = pd.concat([y.reset_index(drop = True), pd.DataFrame(calc_X)], axis = 1)"]},{"cell_type":"markdown","id":"a55e5ebd","metadata":{"papermill":{"duration":0.018578,"end_time":"2024-06-14T18:09:23.25517","exception":false,"start_time":"2024-06-14T18:09:23.236592","status":"completed"},"tags":[]},"source":["# Function to Find Companies Similar To Target"]},{"cell_type":"code","execution_count":54,"id":"67b2e0c5","metadata":{"execution":{"iopub.execute_input":"2024-06-14T18:09:23.294027Z","iopub.status.busy":"2024-06-14T18:09:23.293613Z","iopub.status.idle":"2024-06-14T18:09:23.304798Z","shell.execute_reply":"2024-06-14T18:09:23.30359Z"},"papermill":{"duration":0.033962,"end_time":"2024-06-14T18:09:23.307266","exception":false,"start_time":"2024-06-14T18:09:23.273304","status":"completed"},"tags":[]},"outputs":[],"source":["import numpy as np\n","from sklearn.metrics.pairwise import cosine_distances\n","\n","def find_closest_organizations(organization_name, df = clin_trials_calc, n=5, prnt=False):\n","    \"\"\"\n","    Find the n closest organization names to the given organization name.\n","\n","    Parameters:\n","    organization_name (str): The organization name to search for, does not have to be exact, but partial string cannot be misspelled.\n","    df (pd.DataFrame): DataFrame containing organization names and feature vectors.\n","    n (int): Number of closest organization names to return.\n","    prnt (bool): Whether to print the results or return them. Default is set to return.\n","\n","    Returns:\n","    If prnt is False: List of the n closest organization names.\n","    If prnt is True: Returns None, prints the list instead.\n","    \"\"\"\n","    # Create a lowercase version of the organization names for comparison\n","    df['Organization Full Name Lower'] = df['Organization Full Name'].str.lower()\n","    organization_name = organization_name.lower()\n","    matches = df['Organization Full Name Lower'].str.contains(organization_name, na=False)\n","\n","    if matches.sum() == 0:\n","        print('ERROR: Organization Not Found in Dataset')\n","        return []\n","    elif matches.sum() > 1:\n","        print('ERROR: Query Results in Multiple Organizations')\n","        return []\n","    else:\n","        idx = matches.idxmax()\n","\n","    # Retrieve the corresponding reduced feature vector\n","    target_vector = df.iloc[idx, 1:-1].values  # Assuming feature vectors start from the second column and 'Organization Full Name Lower' is the last column\n","\n","    # Calculate cosine distances between the target vector and all other vectors\n","    distances = cosine_distances([target_vector], df.iloc[:, 1:-1].values)  # Exclude the organization name columns\n","\n","    # Get the indices of the n smallest distances\n","    closest_indices = np.argsort(distances[0])[:n+1]\n","    \n","    closest_indices = closest_indices[closest_indices != idx]\n","\n","    # Return the closest organization names with original capitalization\n","    closest_orgs = df.iloc[closest_indices]['Organization Full Name'].tolist()\n","    if prnt:\n","        for number, org in enumerate(closest_orgs, start=1):\n","            print(f\"{number}: {org}\")\n","    else:\n","        return closest_orgs\n"]},{"cell_type":"code","execution_count":55,"id":"9f97f633","metadata":{"execution":{"iopub.execute_input":"2024-06-14T18:09:23.345031Z","iopub.status.busy":"2024-06-14T18:09:23.344627Z","iopub.status.idle":"2024-06-14T18:09:23.349844Z","shell.execute_reply":"2024-06-14T18:09:23.348771Z"},"papermill":{"duration":0.027146,"end_time":"2024-06-14T18:09:23.352385","exception":false,"start_time":"2024-06-14T18:09:23.325239","status":"completed"},"tags":[]},"outputs":[],"source":["# In my opinion the below worked better than a google search. At least for Sarpeta (chosen for my knowledge of the company)\n","\n","# Simply searching for Duchnenne Muscular Dystrophy on Google, which is a specialization of Sarepta, I could not quickly find NS Pharma, \n","# which also specializes in Duchnenne Muscular Dystrophy. \n","\n","# All of the top five except Vertex focuses (or focused) solely on rare diseases, \n","#and even Vertex does significant research in the area as well as genetic research. \n","#All of the top 10 were either focused on rare diseases or CNS diseases. \n"]},{"cell_type":"markdown","id":"864fbaad","metadata":{"papermill":{"duration":0.017986,"end_time":"2024-06-14T18:09:23.389333","exception":false,"start_time":"2024-06-14T18:09:23.371347","status":"completed"},"tags":[]},"source":["## Find the closest organizations to your target here"]},{"cell_type":"code","execution_count":56,"id":"cf699b7d","metadata":{"execution":{"iopub.execute_input":"2024-06-14T18:09:23.42744Z","iopub.status.busy":"2024-06-14T18:09:23.426447Z","iopub.status.idle":"2024-06-14T18:09:23.494356Z","shell.execute_reply":"2024-06-14T18:09:23.492589Z"},"papermill":{"duration":0.090257,"end_time":"2024-06-14T18:09:23.49767","exception":false,"start_time":"2024-06-14T18:09:23.407413","status":"completed"},"tags":[]},"outputs":[{"name":"stdout","output_type":"stream","text":["1: Terumo Europe N.V.\n","2: Biotronik AG\n","3: C. R. Bard\n","4: Cook Group Incorporated\n","5: Carl Zeiss Meditec, Inc.\n","6: Merit Medical Systems, Inc.\n","7: Medtronic - MITG\n","8: W.L.Gore & Associates\n","9: Abbott Medical Devices\n","10: Biotronik, Inc.\n"]}],"source":["find_closest_organizations('trireme', n = 10, prnt = True)"]},{"cell_type":"code","execution_count":57,"id":"98c4e709","metadata":{"execution":{"iopub.execute_input":"2024-06-14T18:09:23.56792Z","iopub.status.busy":"2024-06-14T18:09:23.566431Z","iopub.status.idle":"2024-06-14T18:10:42.67438Z","shell.execute_reply":"2024-06-14T18:10:42.672913Z"},"papermill":{"duration":79.143253,"end_time":"2024-06-14T18:10:42.677346","exception":false,"start_time":"2024-06-14T18:09:23.534093","status":"completed"},"tags":[]},"outputs":[],"source":["tsne = TSNE(n_components=2, random_state=42)\n","tsne_results = tsne.fit_transform(X)\n","tsne_results_df = pd.DataFrame(tsne_results, columns=['t-SNE Component 1', 't-SNE Component 2'])\n","\n","# Add 'Organization Full Name' column to tsne_results_df\n","tsne_results_df['Organization Full Name'] = clin_trials_calc['Organization Full Name']"]},{"cell_type":"code","execution_count":58,"id":"31d6bab0","metadata":{"execution":{"iopub.execute_input":"2024-06-14T18:10:42.715522Z","iopub.status.busy":"2024-06-14T18:10:42.715073Z","iopub.status.idle":"2024-06-14T18:10:42.723888Z","shell.execute_reply":"2024-06-14T18:10:42.722963Z"},"papermill":{"duration":0.030297,"end_time":"2024-06-14T18:10:42.725952","exception":false,"start_time":"2024-06-14T18:10:42.695655","status":"completed"},"tags":[]},"outputs":[],"source":["def plot_closest_organizations(target_org, n_closest=25):\n","    \"\"\"\n","    Plot the closest organizations to a target organization based on t-SNE results\n","    Assmes tsne dataframe exists.\n","\n","    Parameters:\n","    - target_org (str): The target organization.\n","    - n_closest (int): Number of closest organizations to visualize. Default is 25.\n","    \"\"\"\n","    # Find the closest organizations to the target organization\n","    closest_orgs = find_closest_organizations(target_org, n=n_closest)\n","    # Create an empty figure\n","    fig = go.Figure()\n","\n","    # Iterate through the closest organizations and add them to the plot\n","    for org in closest_orgs:\n","        closest_org_df = tsne_results_df[tsne_results_df['Organization Full Name'] == org]\n","        fig.add_trace(go.Scatter(\n","            x=closest_org_df['t-SNE Component 1'],\n","            y=closest_org_df['t-SNE Component 2'],\n","            mode='markers',\n","            marker=dict(size=8),\n","            name=org,\n","        ))\n","\n","    # Add the target organization with a different marker\n","    target_org_df = tsne_results_df[tsne_results_df['Organization Full Name'].str.contains(target_org, case=False)]\n","    fig.add_trace(go.Scatter(\n","        x=target_org_df['t-SNE Component 1'],\n","        y=target_org_df['t-SNE Component 2'],\n","        mode='markers',\n","        marker=dict(color='blue', size=12, symbol='x'),\n","        name=target_org,\n","    ))\n","\n","    # Update layout\n","    fig.update_layout(\n","        title=f'Closest Organizations to {target_org}',\n","        xaxis_title='t-SNE Component 1',\n","        yaxis_title='t-SNE Component 2',\n","    )\n","\n","    # Show the plot\n","    fig.show()"]},{"cell_type":"markdown","id":"4a06ea7b","metadata":{"papermill":{"duration":0.017689,"end_time":"2024-06-14T18:10:42.761999","exception":false,"start_time":"2024-06-14T18:10:42.74431","status":"completed"},"tags":[]},"source":["# Graphing Based on Company\n","#### Note: this will not be as accurate as the function that simply returns a list in terms of closest to the target. But it might be of interest to see graphical.\n","#### Other Note: The Legend is kept, it is an accurate representation of the order of closeness as determined by the find_closest_organization function"]},{"cell_type":"code","execution_count":59,"id":"3504ad08","metadata":{"execution":{"iopub.execute_input":"2024-06-14T18:10:42.799506Z","iopub.status.busy":"2024-06-14T18:10:42.799105Z","iopub.status.idle":"2024-06-14T18:10:43.290455Z","shell.execute_reply":"2024-06-14T18:10:43.289201Z"},"papermill":{"duration":0.512852,"end_time":"2024-06-14T18:10:43.292743","exception":false,"start_time":"2024-06-14T18:10:42.779891","status":"completed"},"tags":[]},"outputs":[{"data":{"text/html":["        <script type=\"text/javascript\">\n","        window.PlotlyConfig = {MathJaxConfig: 'local'};\n","        if (window.MathJax && window.MathJax.Hub && window.MathJax.Hub.Config) {window.MathJax.Hub.Config({SVG: {font: \"STIX-Web\"}});}\n","        if (typeof require !== 'undefined') {\n","        require.undef(\"plotly\");\n","        requirejs.config({\n","            paths: {\n","                'plotly': ['https://cdn.plot.ly/plotly-2.27.0.min']\n","            }\n","        });\n","        require(['plotly'], function(Plotly) {\n","            window._Plotly = Plotly;\n","        });\n","        }\n","        </script>\n","        "]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<div>                            <div id=\"e83a47df-0406-47cd-8c9e-a991e48fbd40\" class=\"plotly-graph-div\" style=\"height:525px; width:100%;\"></div>            <script type=\"text/javascript\">                require([\"plotly\"], function(Plotly) {                    window.PLOTLYENV=window.PLOTLYENV || {};                                    if (document.getElementById(\"e83a47df-0406-47cd-8c9e-a991e48fbd40\")) {                    Plotly.newPlot(                        \"e83a47df-0406-47cd-8c9e-a991e48fbd40\",                        [{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Terumo Europe N.V.\",\"x\":[42.7551],\"y\":[4.145069],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Biotronik AG\",\"x\":[40.939884],\"y\":[6.9269958],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"C. R. Bard\",\"x\":[14.470045],\"y\":[4.1441765],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Cook Group Incorporated\",\"x\":[14.594404],\"y\":[3.8660169],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Carl Zeiss Meditec, Inc.\",\"x\":[46.24096],\"y\":[6.5246572],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Merit Medical Systems, Inc.\",\"x\":[42.90934],\"y\":[2.840247],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Medtronic - MITG\",\"x\":[46.44269],\"y\":[6.616597],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"W.L.Gore & Associates\",\"x\":[39.27888],\"y\":[3.0087256],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Abbott Medical Devices\",\"x\":[41.616737],\"y\":[4.1553783],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Biotronik, Inc.\",\"x\":[44.906284],\"y\":[4.116007],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Biotronik SE & Co. KG\",\"x\":[44.81056],\"y\":[4.737268],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"B. Braun Melsungen AG\",\"x\":[48.037212],\"y\":[9.386795],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Lombard Medical\",\"x\":[43.24987],\"y\":[8.4081],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Medtronic Cardiac Rhythm and Heart Failure\",\"x\":[41.968914],\"y\":[4.23933],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Philips Healthcare\",\"x\":[45.81004],\"y\":[6.325093],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Terumo Medical Corporation\",\"x\":[39.95511],\"y\":[4.874206],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Integra LifeSciences Corporation\",\"x\":[42.83205],\"y\":[2.5872006],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"MedtronicNeuro\",\"x\":[40.540478],\"y\":[3.9180105],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"LivaNova\",\"x\":[44.811558],\"y\":[4.744502],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Spectranetics Corporation\",\"x\":[14.552406],\"y\":[4.5380573],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Cordis Corporation\",\"x\":[40.53803],\"y\":[5.3197384],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Corindus Inc.\",\"x\":[45.906475],\"y\":[0.53997207],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Nidek Co. LTD.\",\"x\":[47.2337],\"y\":[6.913378],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Medtronic Spinal and Biologics\",\"x\":[13.455528],\"y\":[5.017918],\"type\":\"scatter\"},{\"marker\":{\"size\":8},\"mode\":\"markers\",\"name\":\"Stryker Neurovascular\",\"x\":[46.182465],\"y\":[2.637006],\"type\":\"scatter\"},{\"marker\":{\"color\":\"blue\",\"size\":12,\"symbol\":\"x\"},\"mode\":\"markers\",\"name\":\"trireme\",\"x\":[42.095203],\"y\":[6.4948583],\"type\":\"scatter\"}],                        {\"template\":{\"data\":{\"histogram2dcontour\":[{\"type\":\"histogram2dcontour\",\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"},\"colorscale\":[[0.0,\"#0d0887\"],[0.1111111111111111,\"#46039f\"],[0.2222222222222222,\"#7201a8\"],[0.3333333333333333,\"#9c179e\"],[0.4444444444444444,\"#bd3786\"],[0.5555555555555556,\"#d8576b\"],[0.6666666666666666,\"#ed7953\"],[0.7777777777777778,\"#fb9f3a\"],[0.8888888888888888,\"#fdca26\"],[1.0,\"#f0f921\"]]}],\"choropleth\":[{\"type\":\"choropleth\",\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"}}],\"histogram2d\":[{\"type\":\"histogram2d\",\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"},\"colorscale\":[[0.0,\"#0d0887\"],[0.1111111111111111,\"#46039f\"],[0.2222222222222222,\"#7201a8\"],[0.3333333333333333,\"#9c179e\"],[0.4444444444444444,\"#bd3786\"],[0.5555555555555556,\"#d8576b\"],[0.6666666666666666,\"#ed7953\"],[0.7777777777777778,\"#fb9f3a\"],[0.8888888888888888,\"#fdca26\"],[1.0,\"#f0f921\"]]}],\"heatmap\":[{\"type\":\"heatmap\",\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"},\"colorscale\":[[0.0,\"#0d0887\"],[0.1111111111111111,\"#46039f\"],[0.2222222222222222,\"#7201a8\"],[0.3333333333333333,\"#9c179e\"],[0.4444444444444444,\"#bd3786\"],[0.5555555555555556,\"#d8576b\"],[0.6666666666666666,\"#ed7953\"],[0.7777777777777778,\"#fb9f3a\"],[0.8888888888888888,\"#fdca26\"],[1.0,\"#f0f921\"]]}],\"heatmapgl\":[{\"type\":\"heatmapgl\",\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"},\"colorscale\":[[0.0,\"#0d0887\"],[0.1111111111111111,\"#46039f\"],[0.2222222222222222,\"#7201a8\"],[0.3333333333333333,\"#9c179e\"],[0.4444444444444444,\"#bd3786\"],[0.5555555555555556,\"#d8576b\"],[0.6666666666666666,\"#ed7953\"],[0.7777777777777778,\"#fb9f3a\"],[0.8888888888888888,\"#fdca26\"],[1.0,\"#f0f921\"]]}],\"contourcarpet\":[{\"type\":\"contourcarpet\",\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"}}],\"contour\":[{\"type\":\"contour\",\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"},\"colorscale\":[[0.0,\"#0d0887\"],[0.1111111111111111,\"#46039f\"],[0.2222222222222222,\"#7201a8\"],[0.3333333333333333,\"#9c179e\"],[0.4444444444444444,\"#bd3786\"],[0.5555555555555556,\"#d8576b\"],[0.6666666666666666,\"#ed7953\"],[0.7777777777777778,\"#fb9f3a\"],[0.8888888888888888,\"#fdca26\"],[1.0,\"#f0f921\"]]}],\"surface\":[{\"type\":\"surface\",\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"},\"colorscale\":[[0.0,\"#0d0887\"],[0.1111111111111111,\"#46039f\"],[0.2222222222222222,\"#7201a8\"],[0.3333333333333333,\"#9c179e\"],[0.4444444444444444,\"#bd3786\"],[0.5555555555555556,\"#d8576b\"],[0.6666666666666666,\"#ed7953\"],[0.7777777777777778,\"#fb9f3a\"],[0.8888888888888888,\"#fdca26\"],[1.0,\"#f0f921\"]]}],\"mesh3d\":[{\"type\":\"mesh3d\",\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"}}],\"scatter\":[{\"fillpattern\":{\"fillmode\":\"overlay\",\"size\":10,\"solidity\":0.2},\"type\":\"scatter\"}],\"parcoords\":[{\"type\":\"parcoords\",\"line\":{\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"}}}],\"scatterpolargl\":[{\"type\":\"scatterpolargl\",\"marker\":{\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"}}}],\"bar\":[{\"error_x\":{\"color\":\"#2a3f5f\"},\"error_y\":{\"color\":\"#2a3f5f\"},\"marker\":{\"line\":{\"color\":\"#E5ECF6\",\"width\":0.5},\"pattern\":{\"fillmode\":\"overlay\",\"size\":10,\"solidity\":0.2}},\"type\":\"bar\"}],\"scattergeo\":[{\"type\":\"scattergeo\",\"marker\":{\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"}}}],\"scatterpolar\":[{\"type\":\"scatterpolar\",\"marker\":{\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"}}}],\"histogram\":[{\"marker\":{\"pattern\":{\"fillmode\":\"overlay\",\"size\":10,\"solidity\":0.2}},\"type\":\"histogram\"}],\"scattergl\":[{\"type\":\"scattergl\",\"marker\":{\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"}}}],\"scatter3d\":[{\"type\":\"scatter3d\",\"line\":{\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"}},\"marker\":{\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"}}}],\"scattermapbox\":[{\"type\":\"scattermapbox\",\"marker\":{\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"}}}],\"scatterternary\":[{\"type\":\"scatterternary\",\"marker\":{\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"}}}],\"scattercarpet\":[{\"type\":\"scattercarpet\",\"marker\":{\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"}}}],\"carpet\":[{\"aaxis\":{\"endlinecolor\":\"#2a3f5f\",\"gridcolor\":\"white\",\"linecolor\":\"white\",\"minorgridcolor\":\"white\",\"startlinecolor\":\"#2a3f5f\"},\"baxis\":{\"endlinecolor\":\"#2a3f5f\",\"gridcolor\":\"white\",\"linecolor\":\"white\",\"minorgridcolor\":\"white\",\"startlinecolor\":\"#2a3f5f\"},\"type\":\"carpet\"}],\"table\":[{\"cells\":{\"fill\":{\"color\":\"#EBF0F8\"},\"line\":{\"color\":\"white\"}},\"header\":{\"fill\":{\"color\":\"#C8D4E3\"},\"line\":{\"color\":\"white\"}},\"type\":\"table\"}],\"barpolar\":[{\"marker\":{\"line\":{\"color\":\"#E5ECF6\",\"width\":0.5},\"pattern\":{\"fillmode\":\"overlay\",\"size\":10,\"solidity\":0.2}},\"type\":\"barpolar\"}],\"pie\":[{\"automargin\":true,\"type\":\"pie\"}]},\"layout\":{\"autotypenumbers\":\"strict\",\"colorway\":[\"#636efa\",\"#EF553B\",\"#00cc96\",\"#ab63fa\",\"#FFA15A\",\"#19d3f3\",\"#FF6692\",\"#B6E880\",\"#FF97FF\",\"#FECB52\"],\"font\":{\"color\":\"#2a3f5f\"},\"hovermode\":\"closest\",\"hoverlabel\":{\"align\":\"left\"},\"paper_bgcolor\":\"white\",\"plot_bgcolor\":\"#E5ECF6\",\"polar\":{\"bgcolor\":\"#E5ECF6\",\"angularaxis\":{\"gridcolor\":\"white\",\"linecolor\":\"white\",\"ticks\":\"\"},\"radialaxis\":{\"gridcolor\":\"white\",\"linecolor\":\"white\",\"ticks\":\"\"}},\"ternary\":{\"bgcolor\":\"#E5ECF6\",\"aaxis\":{\"gridcolor\":\"white\",\"linecolor\":\"white\",\"ticks\":\"\"},\"baxis\":{\"gridcolor\":\"white\",\"linecolor\":\"white\",\"ticks\":\"\"},\"caxis\":{\"gridcolor\":\"white\",\"linecolor\":\"white\",\"ticks\":\"\"}},\"coloraxis\":{\"colorbar\":{\"outlinewidth\":0,\"ticks\":\"\"}},\"colorscale\":{\"sequential\":[[0.0,\"#0d0887\"],[0.1111111111111111,\"#46039f\"],[0.2222222222222222,\"#7201a8\"],[0.3333333333333333,\"#9c179e\"],[0.4444444444444444,\"#bd3786\"],[0.5555555555555556,\"#d8576b\"],[0.6666666666666666,\"#ed7953\"],[0.7777777777777778,\"#fb9f3a\"],[0.8888888888888888,\"#fdca26\"],[1.0,\"#f0f921\"]],\"sequentialminus\":[[0.0,\"#0d0887\"],[0.1111111111111111,\"#46039f\"],[0.2222222222222222,\"#7201a8\"],[0.3333333333333333,\"#9c179e\"],[0.4444444444444444,\"#bd3786\"],[0.5555555555555556,\"#d8576b\"],[0.6666666666666666,\"#ed7953\"],[0.7777777777777778,\"#fb9f3a\"],[0.8888888888888888,\"#fdca26\"],[1.0,\"#f0f921\"]],\"diverging\":[[0,\"#8e0152\"],[0.1,\"#c51b7d\"],[0.2,\"#de77ae\"],[0.3,\"#f1b6da\"],[0.4,\"#fde0ef\"],[0.5,\"#f7f7f7\"],[0.6,\"#e6f5d0\"],[0.7,\"#b8e186\"],[0.8,\"#7fbc41\"],[0.9,\"#4d9221\"],[1,\"#276419\"]]},\"xaxis\":{\"gridcolor\":\"white\",\"linecolor\":\"white\",\"ticks\":\"\",\"title\":{\"standoff\":15},\"zerolinecolor\":\"white\",\"automargin\":true,\"zerolinewidth\":2},\"yaxis\":{\"gridcolor\":\"white\",\"linecolor\":\"white\",\"ticks\":\"\",\"title\":{\"standoff\":15},\"zerolinecolor\":\"white\",\"automargin\":true,\"zerolinewidth\":2},\"scene\":{\"xaxis\":{\"backgroundcolor\":\"#E5ECF6\",\"gridcolor\":\"white\",\"linecolor\":\"white\",\"showbackground\":true,\"ticks\":\"\",\"zerolinecolor\":\"white\",\"gridwidth\":2},\"yaxis\":{\"backgroundcolor\":\"#E5ECF6\",\"gridcolor\":\"white\",\"linecolor\":\"white\",\"showbackground\":true,\"ticks\":\"\",\"zerolinecolor\":\"white\",\"gridwidth\":2},\"zaxis\":{\"backgroundcolor\":\"#E5ECF6\",\"gridcolor\":\"white\",\"linecolor\":\"white\",\"showbackground\":true,\"ticks\":\"\",\"zerolinecolor\":\"white\",\"gridwidth\":2}},\"shapedefaults\":{\"line\":{\"color\":\"#2a3f5f\"}},\"annotationdefaults\":{\"arrowcolor\":\"#2a3f5f\",\"arrowhead\":0,\"arrowwidth\":1},\"geo\":{\"bgcolor\":\"white\",\"landcolor\":\"#E5ECF6\",\"subunitcolor\":\"white\",\"showland\":true,\"showlakes\":true,\"lakecolor\":\"white\"},\"title\":{\"x\":0.05},\"mapbox\":{\"style\":\"light\"}}},\"title\":{\"text\":\"Closest Organizations to trireme\"},\"xaxis\":{\"title\":{\"text\":\"t-SNE Component 1\"}},\"yaxis\":{\"title\":{\"text\":\"t-SNE Component 2\"}}},                        {\"responsive\": true}                    ).then(function(){\n","                            \n","var gd = document.getElementById('e83a47df-0406-47cd-8c9e-a991e48fbd40');\n","var x = new MutationObserver(function (mutations, observer) {{\n","        var display = window.getComputedStyle(gd).display;\n","        if (!display || display === 'none') {{\n","            console.log([gd, 'removed!']);\n","            Plotly.purge(gd);\n","            observer.disconnect();\n","        }}\n","}});\n","\n","// Listen for the removal of the full notebook cells\n","var notebookContainer = gd.closest('#notebook-container');\n","if (notebookContainer) {{\n","    x.observe(notebookContainer, {childList: true});\n","}}\n","\n","// Listen for the clearing of the current output cell\n","var outputEl = gd.closest('.output');\n","if (outputEl) {{\n","    x.observe(outputEl, {childList: true});\n","}}\n","\n","                        })                };                });            </script>        </div>"]},"metadata":{},"output_type":"display_data"}],"source":["plot_closest_organizations('trireme')"]},{"cell_type":"markdown","id":"54e16fa9","metadata":{"papermill":{"duration":0.018269,"end_time":"2024-06-14T18:10:43.32973","exception":false,"start_time":"2024-06-14T18:10:43.311461","status":"completed"},"tags":[]},"source":["# Function to return dataframe of studies of the nearest organizations with/without condition"]},{"cell_type":"code","execution_count":60,"id":"abdce637","metadata":{"execution":{"iopub.execute_input":"2024-06-14T18:10:43.368244Z","iopub.status.busy":"2024-06-14T18:10:43.367861Z","iopub.status.idle":"2024-06-14T18:10:43.375267Z","shell.execute_reply":"2024-06-14T18:10:43.374145Z"},"papermill":{"duration":0.02973,"end_time":"2024-06-14T18:10:43.377832","exception":false,"start_time":"2024-06-14T18:10:43.348102","status":"completed"},"tags":[]},"outputs":[],"source":["def filter_df(target_org, condition = None, n = 5):\n","    'Filter study data by companies with or without condition'\n","    '''Parameters: \n","    \n","    target org: the company you are searching for, does not require an exact string, but must be close (no misspellings of the partial string); \n","    best if string is distinct to the organization you are searching for\n","    \n","    condition: the disease that is being studied. Does not require an exact string, but must be close (no misspellings of the partial string)\n","    best if string is distinct to the condition you are searching for\n","    \n","    Returns: filters dataframe in place by companies closest to target with or without condition specified\n","    '''\n","    \n","    closest_orgs = find_closest_organizations(target_org,n= n)\n","    df = clin_trials_ro\n","    df['Organization Full name'] = df['Organization Full Name'].str.lower()\n","    if condition != None:\n","        df = df[df['Conditions'].str.contains(condition)]\n","        df = df[df['Organization Full Name'].isin(closest_orgs)]\n","    else:\n","        df = df[df['Organization Full Name'].isin(closest_orgs)]\n","    return df"]},{"cell_type":"code","execution_count":61,"id":"b2141bc3","metadata":{"execution":{"iopub.execute_input":"2024-06-14T18:10:43.416611Z","iopub.status.busy":"2024-06-14T18:10:43.416158Z","iopub.status.idle":"2024-06-14T18:10:43.715985Z","shell.execute_reply":"2024-06-14T18:10:43.714796Z"},"papermill":{"duration":0.324035,"end_time":"2024-06-14T18:10:43.720467","exception":false,"start_time":"2024-06-14T18:10:43.396432","status":"completed"},"tags":[]},"outputs":[{"data":{"text/html":["<div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>Organization Full Name</th>\n","      <th>Organization Class</th>\n","      <th>Responsible Party</th>\n","      <th>Brief Title</th>\n","      <th>Full Title</th>\n","      <th>Overall Status</th>\n","      <th>Start Date</th>\n","      <th>Standard Age</th>\n","      <th>Conditions</th>\n","      <th>Primary Purpose</th>\n","      <th>Interventions</th>\n","      <th>Intervention Description</th>\n","      <th>Study Type</th>\n","      <th>Phases</th>\n","      <th>Outcome Measure</th>\n","      <th>Medical Subject Headings</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <th>3942</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Compare the PK, PD and Safety and T...</td>\n","      <td>A Randomized, Open-label, Parallel Group Study...</td>\n","      <td>COMPLETED</td>\n","      <td>2017-10-11</td>\n","      <td>ADULT</td>\n","      <td>Bioavailability Study</td>\n","      <td>BASIC_SCIENCE</td>\n","      <td>ARGX-113</td>\n","      <td>intravenous or subcutaneous administration</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE1</td>\n","      <td>bioavailability of a s.c. ARGX-113 formulation</td>\n","      <td>Unknown</td>\n","    </tr>\n","    <tr>\n","      <th>16770</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Safety and Tolerability Study of ARGX-113 in...</td>\n","      <td>A Long-Term, Single-Arm, Open-Label, Multicent...</td>\n","      <td>COMPLETED</td>\n","      <td>2019-03-01</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Generalized Myasthenia Gravis</td>\n","      <td>TREATMENT</td>\n","      <td>ARGX-113</td>\n","      <td>Intravenous administration of ARGX-113</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Number of Participants With Treatment-Emergent...</td>\n","      <td>Myasthenia Gravis Muscle Weakness Paresis</td>\n","    </tr>\n","    <tr>\n","      <th>48185</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study of the Safety and Effectiveness of Efg...</td>\n","      <td>A Phase 2, Randomized, Placebo-controlled, Par...</td>\n","      <td>COMPLETED</td>\n","      <td>2023-04-04</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Primary Sjögren's Syndrome</td>\n","      <td>TREATMENT</td>\n","      <td>Efgartigimod, Placebo</td>\n","      <td>Patients receiving efgartigimod infusions, Pat...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2</td>\n","      <td>Proportion of CRESS responders on ≥3 of 5 item...</td>\n","      <td>Sjogren's Syndrome Syndrome</td>\n","    </tr>\n","    <tr>\n","      <th>52828</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Assess the Safety and Efficacy of a...</td>\n","      <td>A Phase 2 Trial to Investigate the Efficacy, S...</td>\n","      <td>COMPLETED</td>\n","      <td>2020-04-15</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Chronic Inflammatory Demyelinating Polyneuropa...</td>\n","      <td>TREATMENT</td>\n","      <td>efgartigimod PH20 SC in stage B, placebo in st...</td>\n","      <td>Stage A: efgartigimod PH20 SC, Stage B: efgart...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2</td>\n","      <td>Stage A: Percentage of patients with confirmed...</td>\n","      <td>Polyneuropathies Polyradiculoneuropathy, Chron...</td>\n","    </tr>\n","    <tr>\n","      <th>55111</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Clinical Trial to Investigate the Safety, To...</td>\n","      <td>A Phase 1, Randomized, Double-Blinded, Placebo...</td>\n","      <td>RECRUITING</td>\n","      <td>2023-02-21</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Healthy Volunteers</td>\n","      <td>OTHER</td>\n","      <td>ARGX-119, Placebo</td>\n","      <td>Patients receiving ARGX-119 IV or SC, Patients...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE1</td>\n","      <td>Number of treatment-emergent adverse events (T...</td>\n","      <td>Unknown</td>\n","    </tr>\n","    <tr>\n","      <th>71310</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>Efgartigimod Co-administered Subcutaneously Wi...</td>\n","      <td>A Phase 1, Randomized, Open-label, Parallel-gr...</td>\n","      <td>COMPLETED</td>\n","      <td>2019-07-17</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Healthy Volunteers</td>\n","      <td>OTHER</td>\n","      <td>ARGX-113 with rHuPH20</td>\n","      <td>subcutaneous administration of efgartigimod wi...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE1</td>\n","      <td>IgG levels of four different subcutaneous dose...</td>\n","      <td>Unknown</td>\n","    </tr>\n","    <tr>\n","      <th>91603</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Evaluate the Safety, Efficacy, and ...</td>\n","      <td>A Randomized, Double-blind, Placebo-Controlled...</td>\n","      <td>COMPLETED</td>\n","      <td>2016-12-30</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Myasthenia Gravis</td>\n","      <td>TREATMENT</td>\n","      <td>ARGX-113, Placebo</td>\n","      <td>Unknown, Unknown</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2</td>\n","      <td>Number of Patients With Treatment Emergent Adv...</td>\n","      <td>Myasthenia Gravis Muscle Weakness Paresis</td>\n","    </tr>\n","    <tr>\n","      <th>93450</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Prospective Longitudinal Study in Adults Wit...</td>\n","      <td>A Multicenter Prospective Longitudinal Study o...</td>\n","      <td>RECRUITING</td>\n","      <td>2023-11-29</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Multifocal Motor Neuropathy</td>\n","      <td>Unknown</td>\n","      <td>Unknown</td>\n","      <td>Unknown</td>\n","      <td>OBSERVATIONAL</td>\n","      <td>Unknown</td>\n","      <td>To characterize MMN patient profiles for parti...</td>\n","      <td>Neuritis</td>\n","    </tr>\n","    <tr>\n","      <th>108800</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study of Efgartigimod PH20 SC Given by Prefi...</td>\n","      <td>A Phase 3, Randomized, Double-Masked, Placebo-...</td>\n","      <td>RECRUITING</td>\n","      <td>2024-03-28</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Thyroid Eye Disease</td>\n","      <td>TREATMENT</td>\n","      <td>Efgartigimod PH20 SC, Placebo PH20 SC</td>\n","      <td>Subcutaneous efgartigimod PH20 SC given by pre...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Percentage of participants who were proptosis ...</td>\n","      <td>Eye Diseases Graves Ophthalmopathy Thyroid Dis...</td>\n","    </tr>\n","    <tr>\n","      <th>119169</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Phase 3 Study to Evaluate the Safety and Eff...</td>\n","      <td>A Phase 3, Multicenter, Open-Label, Long-Term ...</td>\n","      <td>ACTIVE_NOT_RECRUITING</td>\n","      <td>2021-11-17</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Primary Immune Thrombocytopenia</td>\n","      <td>TREATMENT</td>\n","      <td>efgartigimod PH20 SC</td>\n","      <td>Subcutaneous injection with efgartigimod PH20 SC</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Incidence, frequency, and severity of adverse ...</td>\n","      <td>Thrombocytopenia Purpura, Thrombocytopenic, Id...</td>\n","    </tr>\n","    <tr>\n","      <th>119245</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>SAD and MAD Study With IV and SC Doses of ARGX...</td>\n","      <td>First-In-Human, Randomized, Double-Blinded, Pl...</td>\n","      <td>COMPLETED</td>\n","      <td>2020-08-03</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Healthy Volunteers</td>\n","      <td>OTHER</td>\n","      <td>ARGX-117, Placebo, ARGX-117 + rHuPH20, placebo...</td>\n","      <td>Subjects treated with ARGX-117, Subjects treat...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE1</td>\n","      <td>Number of (S)AE</td>\n","      <td>Unknown</td>\n","    </tr>\n","    <tr>\n","      <th>128354</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study of Efgartigimod PH20 SC in Children Be...</td>\n","      <td>An Open-label, Uncontrolled Study to Evaluate ...</td>\n","      <td>NOT_YET_RECRUITING</td>\n","      <td>2024-05-31</td>\n","      <td>CHILD</td>\n","      <td>Generalized Myasthenia Gravis</td>\n","      <td>TREATMENT</td>\n","      <td>Efgartigimod PH20 SC</td>\n","      <td>Subcutaneous injections</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Efgartigimod serum concentrations as input for...</td>\n","      <td>Myasthenia Gravis Muscle Weakness</td>\n","    </tr>\n","    <tr>\n","      <th>135768</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Evaluate the Safety, PD, PK and Eff...</td>\n","      <td>An Open-label, Non-controlled, Phase II Study ...</td>\n","      <td>COMPLETED</td>\n","      <td>2017-10-18</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Pemphigus Vulgaris, Pemphigus Foliaceus</td>\n","      <td>TREATMENT</td>\n","      <td>ARGX-113</td>\n","      <td>human IgG1-derived Fc fragment that binds to h...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2</td>\n","      <td>Safety and tolerability as measured by the inc...</td>\n","      <td>Pemphigus</td>\n","    </tr>\n","    <tr>\n","      <th>145591</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>Efgartigimod Expanded Access for Generalized M...</td>\n","      <td>An Expanded Access Program for Efgartigimod Tr...</td>\n","      <td>APPROVED_FOR_MARKETING</td>\n","      <td>Unknown</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Generalized Myasthenia Gravis</td>\n","      <td>Unknown</td>\n","      <td>efgartigimod</td>\n","      <td>an intravenous infusion of efgartigimod</td>\n","      <td>EXPANDED_ACCESS</td>\n","      <td>Unknown</td>\n","      <td>Unknown</td>\n","      <td>Myasthenia Gravis Muscle Weakness</td>\n","    </tr>\n","    <tr>\n","      <th>148719</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Assess the Long-term Safety and Eff...</td>\n","      <td>A Phase 3, Single-Arm, Multicenter, Open-label...</td>\n","      <td>RECRUITING</td>\n","      <td>2023-09-12</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Myositis, Active Idiopathic Inflammatory Myopa...</td>\n","      <td>TREATMENT</td>\n","      <td>EFG PH20 SC</td>\n","      <td>Subcutaneous injection of efgartigimod coformu...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Incidence treatment-emergent adverse events an...</td>\n","      <td>Muscular Diseases Dermatomyositis Myositis Pol...</td>\n","    </tr>\n","    <tr>\n","      <th>156362</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study of Efgartigimod PH20 SC Given by Prefi...</td>\n","      <td>A Phase 3, Randomized, Double-Masked, Placebo-...</td>\n","      <td>RECRUITING</td>\n","      <td>2024-03-27</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Thyroid Eye Disease</td>\n","      <td>TREATMENT</td>\n","      <td>Efgartigimod PH20 SC, Placebo PH20 SC</td>\n","      <td>Subcutaneous efgartigimod PH20 SC given by pre...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Percentage of participants who were proptosis ...</td>\n","      <td>Eye Diseases Graves Ophthalmopathy Thyroid Dis...</td>\n","    </tr>\n","    <tr>\n","      <th>162749</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>IV Dose Study to Assess the Safety, Tolerabili...</td>\n","      <td>A Phase I, Randomized, Double-Blind, Placebo-C...</td>\n","      <td>COMPLETED</td>\n","      <td>2015-09-09</td>\n","      <td>ADULT</td>\n","      <td>Healthy Volunteers</td>\n","      <td>OTHER</td>\n","      <td>ARGX-113, Placebo</td>\n","      <td>Unknown, Unknown</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE1</td>\n","      <td>Number of (related) treatment emergent AE of s...</td>\n","      <td>Unknown</td>\n","    </tr>\n","    <tr>\n","      <th>168588</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Phase 1b Study to Investigate Safety and Tol...</td>\n","      <td>A Phase 1b, Double-Blinded, Randomized, Placeb...</td>\n","      <td>NOT_YET_RECRUITING</td>\n","      <td>2024-06</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Congenital Myasthenic Syndrome</td>\n","      <td>TREATMENT</td>\n","      <td>ARGX-119, Placebo</td>\n","      <td>Intravenous infusion of ARGX-119, Intravenous ...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE1</td>\n","      <td>Assessment of adverse events (AEs)</td>\n","      <td>Lambert-Eaton Myasthenic Syndrome Myasthenic S...</td>\n","    </tr>\n","    <tr>\n","      <th>178362</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Phase 2/3 Study of Efgartigimod PH20 SC in A...</td>\n","      <td>A Phase 2/3, Randomized, Double-Blinded, Place...</td>\n","      <td>ACTIVE_NOT_RECRUITING</td>\n","      <td>2022-06-09</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Bullous Pemphigoid</td>\n","      <td>TREATMENT</td>\n","      <td>efgartigimod PH20 SC, placebo, Prednisone</td>\n","      <td>Subcutaneous injection of efgartigimod coformu...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2, PHASE3</td>\n","      <td>Proportion of participants who are in complete...</td>\n","      <td>Pemphigoid, Bullous</td>\n","    </tr>\n","    <tr>\n","      <th>181712</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Assess the Efficacy and Safety of E...</td>\n","      <td>A Phase 3, Multicenter, Randomized, Double-Bli...</td>\n","      <td>WITHDRAWN</td>\n","      <td>2020-06-29</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Primary Immune Thrombocytopenia (ITP)</td>\n","      <td>TREATMENT</td>\n","      <td>efgartigimod, Placebo</td>\n","      <td>Intravenous infusion of efgartigimod, Intraven...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Number of cumulative weeks over the planned 24...</td>\n","      <td>Thrombocytopenia Purpura, Thrombocytopenic, Id...</td>\n","    </tr>\n","    <tr>\n","      <th>188839</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Test How Kidney Problems Influence ...</td>\n","      <td>A Phase 1, Open-label, Study to Evaluate the P...</td>\n","      <td>ACTIVE_NOT_RECRUITING</td>\n","      <td>2023-07-17</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Renal Impairment</td>\n","      <td>OTHER</td>\n","      <td>Efgartigimod IV</td>\n","      <td>Intravenous infusion of efgartigimod</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE1</td>\n","      <td>Efgartigimod PK parameters (Cmax)</td>\n","      <td>Renal Insufficiency</td>\n","    </tr>\n","    <tr>\n","      <th>203828</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>Open Label Extension of Efgartigimod in Adults...</td>\n","      <td>Open-Label Extension Study to Evaluate the Lon...</td>\n","      <td>ACTIVE_NOT_RECRUITING</td>\n","      <td>2023-06-20</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Post-COVID Postural Orthostatic Tachycardia Sy...</td>\n","      <td>TREATMENT</td>\n","      <td>Efgartigimod</td>\n","      <td>Participants will receive efgartigimod IV 10 m...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2</td>\n","      <td>Incidence and severity of AESIs.</td>\n","      <td>Postural Orthostatic Tachycardia Syndrome Tach...</td>\n","    </tr>\n","    <tr>\n","      <th>206525</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>Evaluating the Long-Term Safety and Tolerabili...</td>\n","      <td>A Long-Term, Single-Arm, Open-label, Multicent...</td>\n","      <td>ACTIVE_NOT_RECRUITING</td>\n","      <td>2021-04-26</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Generalized Myasthenia Gravis</td>\n","      <td>TREATMENT</td>\n","      <td>efgartigimod PH20 SC</td>\n","      <td>Subcutaneous injection with efgartigimod PH20 SC</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Incidence and severity of Adverse Events (AEs)...</td>\n","      <td>Myasthenia Gravis Muscle Weakness</td>\n","    </tr>\n","    <tr>\n","      <th>238957</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Assess the Efficacy and Safety of a...</td>\n","      <td>A Randomized, Double-Blinded, Placebo-Controll...</td>\n","      <td>COMPLETED</td>\n","      <td>2020-12-01</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Pemphigus Vulgaris, Pemphigus Foliaceus</td>\n","      <td>TREATMENT</td>\n","      <td>efgartigimod PH20 SC, Placebo, prednisone</td>\n","      <td>Subcutaneous injection of efgartigimod using r...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Proportion of Pemphigus Vulgaris (PV) particip...</td>\n","      <td>Pemphigus</td>\n","    </tr>\n","    <tr>\n","      <th>242557</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Evaluate Safety and Efficacy of Emp...</td>\n","      <td>A Phase 2, Randomized, Double-Blinded, Placebo...</td>\n","      <td>NOT_YET_RECRUITING</td>\n","      <td>2024-05-10</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Dermatomyositis, Myositis</td>\n","      <td>TREATMENT</td>\n","      <td>Empasiprubart IV, Placebo IV</td>\n","      <td>Intravenous infusion with Empasiprubart IV, In...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2</td>\n","      <td>Incidence and severity of adverse events (AEs)...</td>\n","      <td>Dermatomyositis Myositis</td>\n","    </tr>\n","    <tr>\n","      <th>248166</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Assess the Efficacy and Safety of E...</td>\n","      <td>A Phase 3, Multicenter, Randomized, Double-Bli...</td>\n","      <td>COMPLETED</td>\n","      <td>2019-12-16</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Primary Immune Thrombocytopenia</td>\n","      <td>TREATMENT</td>\n","      <td>efgartigimod, Placebo</td>\n","      <td>Intravenous infusion of efgartigimod, Intraven...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Proportion of patients with chronic ITP with a...</td>\n","      <td>Thrombocytopenia Purpura, Thrombocytopenic, Id...</td>\n","    </tr>\n","    <tr>\n","      <th>261810</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>Evaluating Long-term Safety of Efgartigimod Ad...</td>\n","      <td>A Long-term, Single-Arm, Open-label, Multicent...</td>\n","      <td>RECRUITING</td>\n","      <td>2022-08-18</td>\n","      <td>CHILD ADULT</td>\n","      <td>Generalized Myasthenia Gravis</td>\n","      <td>TREATMENT</td>\n","      <td>Efgartigimod IV or Efgartigimod PH20 SC</td>\n","      <td>Intravenous infusion of Efgartigimod or Subcut...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2, PHASE3</td>\n","      <td>Incidence of adverse events (AEs) Severity of ...</td>\n","      <td>Myasthenia Gravis Muscle Weakness</td>\n","    </tr>\n","    <tr>\n","      <th>276571</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study of ARGX-110 in Patients With Nasophary...</td>\n","      <td>A Pilot, Phase Ib Feasibility Study of ARGX-11...</td>\n","      <td>COMPLETED</td>\n","      <td>2015-02</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Cancer</td>\n","      <td>TREATMENT</td>\n","      <td>ARGX-110</td>\n","      <td>Unknown</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE1</td>\n","      <td>Incidence and grading of AEs</td>\n","      <td>Nasopharyngeal Carcinoma</td>\n","    </tr>\n","    <tr>\n","      <th>284369</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>An Open-label Study to Investigate the Clinica...</td>\n","      <td>A Phase 3b, Randomized, Open-label, Parallel-G...</td>\n","      <td>ACTIVE_NOT_RECRUITING</td>\n","      <td>2021-12-16</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Generalized Myasthenia Gravis</td>\n","      <td>TREATMENT</td>\n","      <td>Efgartigimod concentrate for solution for infu...</td>\n","      <td>Patients receiving efgartigimod IV treatment i...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Mean of the average Myasthenia Gravis - Activi...</td>\n","      <td>Myasthenia Gravis Muscle Weakness</td>\n","    </tr>\n","    <tr>\n","      <th>287036</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Phase 3 Study to Evaluate the Long-term Safe...</td>\n","      <td>An Open-label Extension Study of ARGX-113-2009...</td>\n","      <td>RECRUITING</td>\n","      <td>2023-03-22</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Bullous Pemphigoid</td>\n","      <td>TREATMENT</td>\n","      <td>efgartigimod PH20 SC, Prednisone</td>\n","      <td>Subcutaneous injection of efgartigimod coformu...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Incidence of treatment-emergent adverse events...</td>\n","      <td>Pemphigoid, Bullous</td>\n","    </tr>\n","    <tr>\n","      <th>302451</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Evaluate the Efficacy and Safety of...</td>\n","      <td>A Phase 3, Multicenter, Randomized, Double-Bli...</td>\n","      <td>COMPLETED</td>\n","      <td>2020-12-11</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Primary Immune Thrombocytopenia</td>\n","      <td>TREATMENT</td>\n","      <td>Efgartigimod PH20 SC, Placebo PH20 SC</td>\n","      <td>Subcutaneous injection with efgartigimod PH20 ...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Proportion of patients with chronic ITP with a...</td>\n","      <td>Thrombocytopenia Purpura, Thrombocytopenic, Id...</td>\n","    </tr>\n","    <tr>\n","      <th>309956</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Investigate the Efficacy and Safety...</td>\n","      <td>A Phase 2/3, Randomized, Double-Blinded, Place...</td>\n","      <td>RECRUITING</td>\n","      <td>2022-10-12</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Active Idiopathic Inflammatory Myopathy, Myosi...</td>\n","      <td>TREATMENT</td>\n","      <td>EFG PH20 SC, PBO</td>\n","      <td>Subcutaneous injection of efgartigimod coformu...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2, PHASE3</td>\n","      <td>Total improvement score (TIS); measured on a [...</td>\n","      <td>Muscular Diseases Dermatomyositis Myositis Pol...</td>\n","    </tr>\n","    <tr>\n","      <th>331329</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>Evaluating the Pharmacokinetics, Pharmacodynam...</td>\n","      <td>Open-label Uncontrolled Trial to Evaluate Phar...</td>\n","      <td>RECRUITING</td>\n","      <td>2021-10-26</td>\n","      <td>CHILD ADULT</td>\n","      <td>Generalized Myasthenia Gravis</td>\n","      <td>TREATMENT</td>\n","      <td>Efgartigimod IV</td>\n","      <td>Intravenous infusion of Efgartigimod</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2, PHASE3</td>\n","      <td>Efgartigimod concentrations as input for compa...</td>\n","      <td>Myasthenia Gravis Muscle Weakness</td>\n","    </tr>\n","    <tr>\n","      <th>352764</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Non-interventional, Post-authorisation Safet...</td>\n","      <td>A Non-interventional, Post-authorisation Safet...</td>\n","      <td>NOT_YET_RECRUITING</td>\n","      <td>2024-06</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Myasthenia Gravis</td>\n","      <td>Unknown</td>\n","      <td>efgartigimod</td>\n","      <td>efgartigimod</td>\n","      <td>OBSERVATIONAL</td>\n","      <td>Unknown</td>\n","      <td>The overall long-term safety of efgartigimod i...</td>\n","      <td>Myasthenia Gravis</td>\n","    </tr>\n","    <tr>\n","      <th>355889</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Phase 1 Study to Compare the Safety and Effe...</td>\n","      <td>A Phase 1, Randomized, Open-Label, Parallel-Gr...</td>\n","      <td>COMPLETED</td>\n","      <td>2020-08-18</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Healthy Volunteers</td>\n","      <td>TREATMENT</td>\n","      <td>efgartigimod IV, efgartigimod PH20 SC</td>\n","      <td>intravenous infusions of efgartigimod, subcuta...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE1</td>\n","      <td>Percentage reduction in total IgG levels, comp...</td>\n","      <td>Unknown</td>\n","    </tr>\n","    <tr>\n","      <th>356425</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Phase 1b Study of ARGX-111 in Patients With ...</td>\n","      <td>A Phase 1b Study of ARGX-111 in Patients With ...</td>\n","      <td>COMPLETED</td>\n","      <td>2014-01</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Cancer</td>\n","      <td>TREATMENT</td>\n","      <td>ARGX-111</td>\n","      <td>Unknown</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE1</td>\n","      <td>Dose-limiting toxicity</td>\n","      <td>Unknown</td>\n","    </tr>\n","    <tr>\n","      <th>361692</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>Open-Label Extension Study to Evaluate the Saf...</td>\n","      <td>Open-Label Extension Study to Evaluate the Saf...</td>\n","      <td>ACTIVE_NOT_RECRUITING</td>\n","      <td>2023-08-15</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Primary Sjögren's Syndrome</td>\n","      <td>TREATMENT</td>\n","      <td>Efgartigimod</td>\n","      <td>Patients receiving efgartigimod infusions</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2</td>\n","      <td>Number of participants with (serious) adverse ...</td>\n","      <td>Sjogren's Syndrome Syndrome</td>\n","    </tr>\n","    <tr>\n","      <th>364433</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Assess Effectiveness and Safety of ...</td>\n","      <td>A Multicenter, Randomized, Double-Blinded, Pla...</td>\n","      <td>RECRUITING</td>\n","      <td>2023-02-21</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Lupus Nephritis</td>\n","      <td>TREATMENT</td>\n","      <td>efgartigimod IV, Placebo</td>\n","      <td>infusion of efgartigimod, infusion of placebo</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2</td>\n","      <td>Change from baseline to week 24 in urine prote...</td>\n","      <td>Nephritis Lupus Nephritis</td>\n","    </tr>\n","    <tr>\n","      <th>364648</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Worldwide Pregnancy Safety Study to Assess M...</td>\n","      <td>A Worldwide Pregnancy Safety Study To Assess M...</td>\n","      <td>RECRUITING</td>\n","      <td>2024-05-02</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Myasthenia Gravis</td>\n","      <td>Unknown</td>\n","      <td>Efgartigimod</td>\n","      <td>Efgartigimod IV or SC</td>\n","      <td>OBSERVATIONAL</td>\n","      <td>Unknown</td>\n","      <td>Pregnancy outcomes</td>\n","      <td>Myasthenia Gravis</td>\n","    </tr>\n","    <tr>\n","      <th>381128</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Phase 1 Bioequivalence Study of Efgartigimod...</td>\n","      <td>A Phase 1, Randomized, Open-label, Parallel-Gr...</td>\n","      <td>COMPLETED</td>\n","      <td>2023-03-13</td>\n","      <td>ADULT</td>\n","      <td>Bioequivalence</td>\n","      <td>OTHER</td>\n","      <td>efgartigimod PH20 SC as a prefilled syringe pr...</td>\n","      <td>efgartigimod PH20 SC as a prefilled syringe pr...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE1</td>\n","      <td>Primary PK parameters (Cmax) Primary PK parame...</td>\n","      <td>Unknown</td>\n","    </tr>\n","    <tr>\n","      <th>385626</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>ARGX-117 in Deceased Donor Kidney Transplant R...</td>\n","      <td>A Phase 2, Multicenter, Randomized, Double-Bli...</td>\n","      <td>RECRUITING</td>\n","      <td>2024-02-17</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Delayed Graft Function</td>\n","      <td>TREATMENT</td>\n","      <td>ARGX-117, Placebo</td>\n","      <td>Intravenous administration of ARGX-117, Intrav...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2</td>\n","      <td>eGFR at 24 weeks posttransplant</td>\n","      <td>Delayed Graft Function</td>\n","    </tr>\n","    <tr>\n","      <th>393865</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>Immune Response to PNEUMOVAX 23 in Healthy Adu...</td>\n","      <td>A Randomized, Open-label, Placebo-Controlled, ...</td>\n","      <td>COMPLETED</td>\n","      <td>2021-11-17</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Healthy Volunteers</td>\n","      <td>OTHER</td>\n","      <td>Efgartigimod, Placebo, PNEUMOVAX 23</td>\n","      <td>intravenous infusion of efgartigimod, intraven...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE1</td>\n","      <td>Variation in the immune response assessed by c...</td>\n","      <td>Unknown</td>\n","    </tr>\n","    <tr>\n","      <th>402726</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Assess the Long-term Safety and Eff...</td>\n","      <td>Open-label Extension of the ARGX-113-1802 Tria...</td>\n","      <td>ACTIVE_NOT_RECRUITING</td>\n","      <td>2020-09-18</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Chronic Inflammatory Demyelinating Polyneuropa...</td>\n","      <td>TREATMENT</td>\n","      <td>Efgartigimod PH20 SC</td>\n","      <td>Subcutaneous administration of efgartigimod</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2</td>\n","      <td>Incidence of treatment-emergent adverse events...</td>\n","      <td>Polyneuropathies Polyradiculoneuropathy, Chron...</td>\n","    </tr>\n","    <tr>\n","      <th>422773</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Clinical Trial to Investigate the Safety and...</td>\n","      <td>A Phase 2, Randomized, Double-Blinded, Placebo...</td>\n","      <td>ACTIVE_NOT_RECRUITING</td>\n","      <td>2022-03-31</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Multifocal Motor Neuropathy</td>\n","      <td>TREATMENT</td>\n","      <td>ARGX-117, Placebo</td>\n","      <td>Intravenous administration of ARGX-117, Intrav...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2</td>\n","      <td>Safety outcomes based on adverse event (AE) mo...</td>\n","      <td>Neuritis</td>\n","    </tr>\n","    <tr>\n","      <th>431641</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Phase 3 Study to Evaluate the Efficacy and S...</td>\n","      <td>A Randomized, Double-Blinded, Placebo-Controll...</td>\n","      <td>RECRUITING</td>\n","      <td>2024-04-16</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Generalized Myasthenia Gravis</td>\n","      <td>TREATMENT</td>\n","      <td>Efgartigimod IV, Placebo IV</td>\n","      <td>Intravenous infusion of efgartigimod, Intraven...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Myasthenia Gravis Activities of Daily Living (...</td>\n","      <td>Myasthenia Gravis Muscle Weakness</td>\n","    </tr>\n","    <tr>\n","      <th>432758</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>Evaluating the Pharmacodynamic Noninferiority ...</td>\n","      <td>A Phase 3, Randomized, Open-Label, Parallel-Gr...</td>\n","      <td>COMPLETED</td>\n","      <td>2021-02-05</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Generalized Myasthenia Gravis</td>\n","      <td>TREATMENT</td>\n","      <td>efgartigimod PH20 SC, efgartigimod IV</td>\n","      <td>Subcutaneous injection with efgartigimod PH20 ...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Percent Change From Baseline in Total IgG Leve...</td>\n","      <td>Myasthenia Gravis Muscle Weakness</td>\n","    </tr>\n","    <tr>\n","      <th>443965</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Long-term Study to Assess the Safety and Eff...</td>\n","      <td>A Phase 3, Multicenter, Open-label, Long-term ...</td>\n","      <td>ACTIVE_NOT_RECRUITING</td>\n","      <td>2020-06-02</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Primary Immune Thrombocytopenia</td>\n","      <td>TREATMENT</td>\n","      <td>efgartigimod</td>\n","      <td>Intravenous infusion of efgartigimod</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Frequency and severity of Adverse Events Frequ...</td>\n","      <td>Thrombocytopenia Purpura, Thrombocytopenic, Id...</td>\n","    </tr>\n","    <tr>\n","      <th>447762</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>Efficacy and Safety Study of Efgartigimod in A...</td>\n","      <td>A Phase 2 Randomized, Double-blinded, Placebo-...</td>\n","      <td>COMPLETED</td>\n","      <td>2022-09-23</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Postural Orthostatic Tachycardia Syndrome</td>\n","      <td>TREATMENT</td>\n","      <td>Efgartigimod, Placebo</td>\n","      <td>Efgartigimod IV 10 mg/kg infusion qw for 24 we...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2</td>\n","      <td>Evaluate the efficacy of efgartigimod in reduc...</td>\n","      <td>Postural Orthostatic Tachycardia Syndrome Tach...</td>\n","    </tr>\n","    <tr>\n","      <th>451446</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>An Efficacy and Safety Study of ARGX-113 in Pa...</td>\n","      <td>A Randomized, Double-Blind, Placebo-Controlled...</td>\n","      <td>COMPLETED</td>\n","      <td>2018-08-22</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Generalized Myasthenia Gravis</td>\n","      <td>TREATMENT</td>\n","      <td>ARGX-113, Placebo</td>\n","      <td>Intravenous administration of ARGX-113, Intrav...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Percentage of MG-ADL Responders During Cycle 1...</td>\n","      <td>Myasthenia Gravis Muscle Weakness Paresis</td>\n","    </tr>\n","    <tr>\n","      <th>457340</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Evaluate the Safety, Efficacy, and ...</td>\n","      <td>A Randomized, Double-blind, Placebo-controlled...</td>\n","      <td>COMPLETED</td>\n","      <td>2017-03-13</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Primary Immune Thrombocytopenia</td>\n","      <td>TREATMENT</td>\n","      <td>ARGX-113, Placebo</td>\n","      <td>ARGX-113 (Dose A or Dose B) or matching placeb...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2</td>\n","      <td>Incidence and severity of serious adverse even...</td>\n","      <td>Thrombocytopenia Purpura, Thrombocytopenic, Id...</td>\n","    </tr>\n","    <tr>\n","      <th>465975</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Clinical Trial to Investigate the Long-term ...</td>\n","      <td>A Long-term Extension of the ARGX-117-2002 Tri...</td>\n","      <td>RECRUITING</td>\n","      <td>2023-01-18</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Multifocal Motor Neuropathy (MMN)</td>\n","      <td>TREATMENT</td>\n","      <td>ARGX-117, Placebo</td>\n","      <td>Intravenous administration of ARGX-117, Intrav...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2</td>\n","      <td>Safety outcomes based on adverse event (AE) mo...</td>\n","      <td>Neuritis</td>\n","    </tr>\n","    <tr>\n","      <th>466710</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Assess Effectiveness and Safety of ...</td>\n","      <td>A Multicenter, Randomized, Double-blinded, Pla...</td>\n","      <td>RECRUITING</td>\n","      <td>2023-02-20</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Membranous Nephropathy</td>\n","      <td>TREATMENT</td>\n","      <td>efgartigimod IV, placebo</td>\n","      <td>infusion of efgartigimod, infusion of placebo</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE2</td>\n","      <td>Change from baseline to week 24 in urine prote...</td>\n","      <td>Kidney Diseases Glomerulonephritis, Membranous</td>\n","    </tr>\n","    <tr>\n","      <th>483658</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Study to Assess the Long-term Safety and Eff...</td>\n","      <td>An Open-Label, Multicenter, Follow-up Trial of...</td>\n","      <td>TERMINATED</td>\n","      <td>2021-07-15</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Pemphigus Vulgaris, Pemphigus Foliaceus</td>\n","      <td>TREATMENT</td>\n","      <td>efgartigimod PH20 SC, prednisone</td>\n","      <td>Subcutaneous injection of efgartigimod using r...</td>\n","      <td>INTERVENTIONAL</td>\n","      <td>PHASE3</td>\n","      <td>Incidence of Treatment-Emergent Adverse Events...</td>\n","      <td>Pemphigus</td>\n","    </tr>\n","    <tr>\n","      <th>485813</th>\n","      <td>argenx</td>\n","      <td>INDUSTRY</td>\n","      <td>SPONSOR</td>\n","      <td>A Natural History Study in Participants With D...</td>\n","      <td>Multicenter, Multinational, Natural History St...</td>\n","      <td>RECRUITING</td>\n","      <td>2024-02-13</td>\n","      <td>ADULT OLDER_ADULT</td>\n","      <td>Congenital Myasthenic Syndrome</td>\n","      <td>Unknown</td>\n","      <td>Unknown</td>\n","      <td>Unknown</td>\n","      <td>OBSERVATIONAL</td>\n","      <td>Unknown</td>\n","      <td>Summary statistics of retrospective and prospe...</td>\n","      <td>Lambert-Eaton Myasthenic Syndrome Myasthenic S...</td>\n","    </tr>\n","  </tbody>\n","</table>\n","</div>"],"text/plain":["       Organization Full Name Organization Class Responsible Party  \\\n","3942                   argenx           INDUSTRY           SPONSOR   \n","16770                  argenx           INDUSTRY           SPONSOR   \n","48185                  argenx           INDUSTRY           SPONSOR   \n","52828                  argenx           INDUSTRY           SPONSOR   \n","55111                  argenx           INDUSTRY           SPONSOR   \n","71310                  argenx           INDUSTRY           SPONSOR   \n","91603                  argenx           INDUSTRY           SPONSOR   \n","93450                  argenx           INDUSTRY           SPONSOR   \n","108800                 argenx           INDUSTRY           SPONSOR   \n","119169                 argenx           INDUSTRY           SPONSOR   \n","119245                 argenx           INDUSTRY           SPONSOR   \n","128354                 argenx           INDUSTRY           SPONSOR   \n","135768                 argenx           INDUSTRY           SPONSOR   \n","145591                 argenx           INDUSTRY           SPONSOR   \n","148719                 argenx           INDUSTRY           SPONSOR   \n","156362                 argenx           INDUSTRY           SPONSOR   \n","162749                 argenx           INDUSTRY           SPONSOR   \n","168588                 argenx           INDUSTRY           SPONSOR   \n","178362                 argenx           INDUSTRY           SPONSOR   \n","181712                 argenx           INDUSTRY           SPONSOR   \n","188839                 argenx           INDUSTRY           SPONSOR   \n","203828                 argenx           INDUSTRY           SPONSOR   \n","206525                 argenx           INDUSTRY           SPONSOR   \n","238957                 argenx           INDUSTRY           SPONSOR   \n","242557                 argenx           INDUSTRY           SPONSOR   \n","248166                 argenx           INDUSTRY           SPONSOR   \n","261810                 argenx           INDUSTRY           SPONSOR   \n","276571                 argenx           INDUSTRY           SPONSOR   \n","284369                 argenx           INDUSTRY           SPONSOR   \n","287036                 argenx           INDUSTRY           SPONSOR   \n","302451                 argenx           INDUSTRY           SPONSOR   \n","309956                 argenx           INDUSTRY           SPONSOR   \n","331329                 argenx           INDUSTRY           SPONSOR   \n","352764                 argenx           INDUSTRY           SPONSOR   \n","355889                 argenx           INDUSTRY           SPONSOR   \n","356425                 argenx           INDUSTRY           SPONSOR   \n","361692                 argenx           INDUSTRY           SPONSOR   \n","364433                 argenx           INDUSTRY           SPONSOR   \n","364648                 argenx           INDUSTRY           SPONSOR   \n","381128                 argenx           INDUSTRY           SPONSOR   \n","385626                 argenx           INDUSTRY           SPONSOR   \n","393865                 argenx           INDUSTRY           SPONSOR   \n","402726                 argenx           INDUSTRY           SPONSOR   \n","422773                 argenx           INDUSTRY           SPONSOR   \n","431641                 argenx           INDUSTRY           SPONSOR   \n","432758                 argenx           INDUSTRY           SPONSOR   \n","443965                 argenx           INDUSTRY           SPONSOR   \n","447762                 argenx           INDUSTRY           SPONSOR   \n","451446                 argenx           INDUSTRY           SPONSOR   \n","457340                 argenx           INDUSTRY           SPONSOR   \n","465975                 argenx           INDUSTRY           SPONSOR   \n","466710                 argenx           INDUSTRY           SPONSOR   \n","483658                 argenx           INDUSTRY           SPONSOR   \n","485813                 argenx           INDUSTRY           SPONSOR   \n","\n","                                              Brief Title  \\\n","3942    A Study to Compare the PK, PD and Safety and T...   \n","16770   A Safety and Tolerability Study of ARGX-113 in...   \n","48185   A Study of the Safety and Effectiveness of Efg...   \n","52828   A Study to Assess the Safety and Efficacy of a...   \n","55111   A Clinical Trial to Investigate the Safety, To...   \n","71310   Efgartigimod Co-administered Subcutaneously Wi...   \n","91603   A Study to Evaluate the Safety, Efficacy, and ...   \n","93450   A Prospective Longitudinal Study in Adults Wit...   \n","108800  A Study of Efgartigimod PH20 SC Given by Prefi...   \n","119169  A Phase 3 Study to Evaluate the Safety and Eff...   \n","119245  SAD and MAD Study With IV and SC Doses of ARGX...   \n","128354  A Study of Efgartigimod PH20 SC in Children Be...   \n","135768  A Study to Evaluate the Safety, PD, PK and Eff...   \n","145591  Efgartigimod Expanded Access for Generalized M...   \n","148719  A Study to Assess the Long-term Safety and Eff...   \n","156362  A Study of Efgartigimod PH20 SC Given by Prefi...   \n","162749  IV Dose Study to Assess the Safety, Tolerabili...   \n","168588  A Phase 1b Study to Investigate Safety and Tol...   \n","178362  A Phase 2/3 Study of Efgartigimod PH20 SC in A...   \n","181712  A Study to Assess the Efficacy and Safety of E...   \n","188839  A Study to Test How Kidney Problems Influence ...   \n","203828  Open Label Extension of Efgartigimod in Adults...   \n","206525  Evaluating the Long-Term Safety and Tolerabili...   \n","238957  A Study to Assess the Efficacy and Safety of a...   \n","242557  A Study to Evaluate Safety and Efficacy of Emp...   \n","248166  A Study to Assess the Efficacy and Safety of E...   \n","261810  Evaluating Long-term Safety of Efgartigimod Ad...   \n","276571  A Study of ARGX-110 in Patients With Nasophary...   \n","284369  An Open-label Study to Investigate the Clinica...   \n","287036  A Phase 3 Study to Evaluate the Long-term Safe...   \n","302451  A Study to Evaluate the Efficacy and Safety of...   \n","309956  A Study to Investigate the Efficacy and Safety...   \n","331329  Evaluating the Pharmacokinetics, Pharmacodynam...   \n","352764  A Non-interventional, Post-authorisation Safet...   \n","355889  A Phase 1 Study to Compare the Safety and Effe...   \n","356425  A Phase 1b Study of ARGX-111 in Patients With ...   \n","361692  Open-Label Extension Study to Evaluate the Saf...   \n","364433  A Study to Assess Effectiveness and Safety of ...   \n","364648  A Worldwide Pregnancy Safety Study to Assess M...   \n","381128  A Phase 1 Bioequivalence Study of Efgartigimod...   \n","385626  ARGX-117 in Deceased Donor Kidney Transplant R...   \n","393865  Immune Response to PNEUMOVAX 23 in Healthy Adu...   \n","402726  A Study to Assess the Long-term Safety and Eff...   \n","422773  A Clinical Trial to Investigate the Safety and...   \n","431641  A Phase 3 Study to Evaluate the Efficacy and S...   \n","432758  Evaluating the Pharmacodynamic Noninferiority ...   \n","443965  A Long-term Study to Assess the Safety and Eff...   \n","447762  Efficacy and Safety Study of Efgartigimod in A...   \n","451446  An Efficacy and Safety Study of ARGX-113 in Pa...   \n","457340  A Study to Evaluate the Safety, Efficacy, and ...   \n","465975  A Clinical Trial to Investigate the Long-term ...   \n","466710  A Study to Assess Effectiveness and Safety of ...   \n","483658  A Study to Assess the Long-term Safety and Eff...   \n","485813  A Natural History Study in Participants With D...   \n","\n","                                               Full Title  \\\n","3942    A Randomized, Open-label, Parallel Group Study...   \n","16770   A Long-Term, Single-Arm, Open-Label, Multicent...   \n","48185   A Phase 2, Randomized, Placebo-controlled, Par...   \n","52828   A Phase 2 Trial to Investigate the Efficacy, S...   \n","55111   A Phase 1, Randomized, Double-Blinded, Placebo...   \n","71310   A Phase 1, Randomized, Open-label, Parallel-gr...   \n","91603   A Randomized, Double-blind, Placebo-Controlled...   \n","93450   A Multicenter Prospective Longitudinal Study o...   \n","108800  A Phase 3, Randomized, Double-Masked, Placebo-...   \n","119169  A Phase 3, Multicenter, Open-Label, Long-Term ...   \n","119245  First-In-Human, Randomized, Double-Blinded, Pl...   \n","128354  An Open-label, Uncontrolled Study to Evaluate ...   \n","135768  An Open-label, Non-controlled, Phase II Study ...   \n","145591  An Expanded Access Program for Efgartigimod Tr...   \n","148719  A Phase 3, Single-Arm, Multicenter, Open-label...   \n","156362  A Phase 3, Randomized, Double-Masked, Placebo-...   \n","162749  A Phase I, Randomized, Double-Blind, Placebo-C...   \n","168588  A Phase 1b, Double-Blinded, Randomized, Placeb...   \n","178362  A Phase 2/3, Randomized, Double-Blinded, Place...   \n","181712  A Phase 3, Multicenter, Randomized, Double-Bli...   \n","188839  A Phase 1, Open-label, Study to Evaluate the P...   \n","203828  Open-Label Extension Study to Evaluate the Lon...   \n","206525  A Long-Term, Single-Arm, Open-label, Multicent...   \n","238957  A Randomized, Double-Blinded, Placebo-Controll...   \n","242557  A Phase 2, Randomized, Double-Blinded, Placebo...   \n","248166  A Phase 3, Multicenter, Randomized, Double-Bli...   \n","261810  A Long-term, Single-Arm, Open-label, Multicent...   \n","276571  A Pilot, Phase Ib Feasibility Study of ARGX-11...   \n","284369  A Phase 3b, Randomized, Open-label, Parallel-G...   \n","287036  An Open-label Extension Study of ARGX-113-2009...   \n","302451  A Phase 3, Multicenter, Randomized, Double-Bli...   \n","309956  A Phase 2/3, Randomized, Double-Blinded, Place...   \n","331329  Open-label Uncontrolled Trial to Evaluate Phar...   \n","352764  A Non-interventional, Post-authorisation Safet...   \n","355889  A Phase 1, Randomized, Open-Label, Parallel-Gr...   \n","356425  A Phase 1b Study of ARGX-111 in Patients With ...   \n","361692  Open-Label Extension Study to Evaluate the Saf...   \n","364433  A Multicenter, Randomized, Double-Blinded, Pla...   \n","364648  A Worldwide Pregnancy Safety Study To Assess M...   \n","381128  A Phase 1, Randomized, Open-label, Parallel-Gr...   \n","385626  A Phase 2, Multicenter, Randomized, Double-Bli...   \n","393865  A Randomized, Open-label, Placebo-Controlled, ...   \n","402726  Open-label Extension of the ARGX-113-1802 Tria...   \n","422773  A Phase 2, Randomized, Double-Blinded, Placebo...   \n","431641  A Randomized, Double-Blinded, Placebo-Controll...   \n","432758  A Phase 3, Randomized, Open-Label, Parallel-Gr...   \n","443965  A Phase 3, Multicenter, Open-label, Long-term ...   \n","447762  A Phase 2 Randomized, Double-blinded, Placebo-...   \n","451446  A Randomized, Double-Blind, Placebo-Controlled...   \n","457340  A Randomized, Double-blind, Placebo-controlled...   \n","465975  A Long-term Extension of the ARGX-117-2002 Tri...   \n","466710  A Multicenter, Randomized, Double-blinded, Pla...   \n","483658  An Open-Label, Multicenter, Follow-up Trial of...   \n","485813  Multicenter, Multinational, Natural History St...   \n","\n","                Overall Status  Start Date       Standard Age  \\\n","3942                 COMPLETED  2017-10-11              ADULT   \n","16770                COMPLETED  2019-03-01  ADULT OLDER_ADULT   \n","48185                COMPLETED  2023-04-04  ADULT OLDER_ADULT   \n","52828                COMPLETED  2020-04-15  ADULT OLDER_ADULT   \n","55111               RECRUITING  2023-02-21  ADULT OLDER_ADULT   \n","71310                COMPLETED  2019-07-17  ADULT OLDER_ADULT   \n","91603                COMPLETED  2016-12-30  ADULT OLDER_ADULT   \n","93450               RECRUITING  2023-11-29  ADULT OLDER_ADULT   \n","108800              RECRUITING  2024-03-28  ADULT OLDER_ADULT   \n","119169   ACTIVE_NOT_RECRUITING  2021-11-17  ADULT OLDER_ADULT   \n","119245               COMPLETED  2020-08-03  ADULT OLDER_ADULT   \n","128354      NOT_YET_RECRUITING  2024-05-31              CHILD   \n","135768               COMPLETED  2017-10-18  ADULT OLDER_ADULT   \n","145591  APPROVED_FOR_MARKETING     Unknown  ADULT OLDER_ADULT   \n","148719              RECRUITING  2023-09-12  ADULT OLDER_ADULT   \n","156362              RECRUITING  2024-03-27  ADULT OLDER_ADULT   \n","162749               COMPLETED  2015-09-09              ADULT   \n","168588      NOT_YET_RECRUITING     2024-06  ADULT OLDER_ADULT   \n","178362   ACTIVE_NOT_RECRUITING  2022-06-09  ADULT OLDER_ADULT   \n","181712               WITHDRAWN  2020-06-29  ADULT OLDER_ADULT   \n","188839   ACTIVE_NOT_RECRUITING  2023-07-17  ADULT OLDER_ADULT   \n","203828   ACTIVE_NOT_RECRUITING  2023-06-20  ADULT OLDER_ADULT   \n","206525   ACTIVE_NOT_RECRUITING  2021-04-26  ADULT OLDER_ADULT   \n","238957               COMPLETED  2020-12-01  ADULT OLDER_ADULT   \n","242557      NOT_YET_RECRUITING  2024-05-10  ADULT OLDER_ADULT   \n","248166               COMPLETED  2019-12-16  ADULT OLDER_ADULT   \n","261810              RECRUITING  2022-08-18        CHILD ADULT   \n","276571               COMPLETED     2015-02  ADULT OLDER_ADULT   \n","284369   ACTIVE_NOT_RECRUITING  2021-12-16  ADULT OLDER_ADULT   \n","287036              RECRUITING  2023-03-22  ADULT OLDER_ADULT   \n","302451               COMPLETED  2020-12-11  ADULT OLDER_ADULT   \n","309956              RECRUITING  2022-10-12  ADULT OLDER_ADULT   \n","331329              RECRUITING  2021-10-26        CHILD ADULT   \n","352764      NOT_YET_RECRUITING     2024-06  ADULT OLDER_ADULT   \n","355889               COMPLETED  2020-08-18  ADULT OLDER_ADULT   \n","356425               COMPLETED     2014-01  ADULT OLDER_ADULT   \n","361692   ACTIVE_NOT_RECRUITING  2023-08-15  ADULT OLDER_ADULT   \n","364433              RECRUITING  2023-02-21  ADULT OLDER_ADULT   \n","364648              RECRUITING  2024-05-02  ADULT OLDER_ADULT   \n","381128               COMPLETED  2023-03-13              ADULT   \n","385626              RECRUITING  2024-02-17  ADULT OLDER_ADULT   \n","393865               COMPLETED  2021-11-17  ADULT OLDER_ADULT   \n","402726   ACTIVE_NOT_RECRUITING  2020-09-18  ADULT OLDER_ADULT   \n","422773   ACTIVE_NOT_RECRUITING  2022-03-31  ADULT OLDER_ADULT   \n","431641              RECRUITING  2024-04-16  ADULT OLDER_ADULT   \n","432758               COMPLETED  2021-02-05  ADULT OLDER_ADULT   \n","443965   ACTIVE_NOT_RECRUITING  2020-06-02  ADULT OLDER_ADULT   \n","447762               COMPLETED  2022-09-23  ADULT OLDER_ADULT   \n","451446               COMPLETED  2018-08-22  ADULT OLDER_ADULT   \n","457340               COMPLETED  2017-03-13  ADULT OLDER_ADULT   \n","465975              RECRUITING  2023-01-18  ADULT OLDER_ADULT   \n","466710              RECRUITING  2023-02-20  ADULT OLDER_ADULT   \n","483658              TERMINATED  2021-07-15  ADULT OLDER_ADULT   \n","485813              RECRUITING  2024-02-13  ADULT OLDER_ADULT   \n","\n","                                               Conditions Primary Purpose  \\\n","3942                                Bioavailability Study   BASIC_SCIENCE   \n","16770                       Generalized Myasthenia Gravis       TREATMENT   \n","48185                          Primary Sjögren's Syndrome       TREATMENT   \n","52828   Chronic Inflammatory Demyelinating Polyneuropa...       TREATMENT   \n","55111                                  Healthy Volunteers           OTHER   \n","71310                                  Healthy Volunteers           OTHER   \n","91603                                   Myasthenia Gravis       TREATMENT   \n","93450                         Multifocal Motor Neuropathy         Unknown   \n","108800                                Thyroid Eye Disease       TREATMENT   \n","119169                    Primary Immune Thrombocytopenia       TREATMENT   \n","119245                                 Healthy Volunteers           OTHER   \n","128354                      Generalized Myasthenia Gravis       TREATMENT   \n","135768            Pemphigus Vulgaris, Pemphigus Foliaceus       TREATMENT   \n","145591                      Generalized Myasthenia Gravis         Unknown   \n","148719  Myositis, Active Idiopathic Inflammatory Myopa...       TREATMENT   \n","156362                                Thyroid Eye Disease       TREATMENT   \n","162749                                 Healthy Volunteers           OTHER   \n","168588                     Congenital Myasthenic Syndrome       TREATMENT   \n","178362                                 Bullous Pemphigoid       TREATMENT   \n","181712              Primary Immune Thrombocytopenia (ITP)       TREATMENT   \n","188839                                   Renal Impairment           OTHER   \n","203828  Post-COVID Postural Orthostatic Tachycardia Sy...       TREATMENT   \n","206525                      Generalized Myasthenia Gravis       TREATMENT   \n","238957            Pemphigus Vulgaris, Pemphigus Foliaceus       TREATMENT   \n","242557                          Dermatomyositis, Myositis       TREATMENT   \n","248166                    Primary Immune Thrombocytopenia       TREATMENT   \n","261810                      Generalized Myasthenia Gravis       TREATMENT   \n","276571                                             Cancer       TREATMENT   \n","284369                      Generalized Myasthenia Gravis       TREATMENT   \n","287036                                 Bullous Pemphigoid       TREATMENT   \n","302451                    Primary Immune Thrombocytopenia       TREATMENT   \n","309956  Active Idiopathic Inflammatory Myopathy, Myosi...       TREATMENT   \n","331329                      Generalized Myasthenia Gravis       TREATMENT   \n","352764                                  Myasthenia Gravis         Unknown   \n","355889                                 Healthy Volunteers       TREATMENT   \n","356425                                             Cancer       TREATMENT   \n","361692                         Primary Sjögren's Syndrome       TREATMENT   \n","364433                                    Lupus Nephritis       TREATMENT   \n","364648                                  Myasthenia Gravis         Unknown   \n","381128                                     Bioequivalence           OTHER   \n","385626                             Delayed Graft Function       TREATMENT   \n","393865                                 Healthy Volunteers           OTHER   \n","402726  Chronic Inflammatory Demyelinating Polyneuropa...       TREATMENT   \n","422773                        Multifocal Motor Neuropathy       TREATMENT   \n","431641                      Generalized Myasthenia Gravis       TREATMENT   \n","432758                      Generalized Myasthenia Gravis       TREATMENT   \n","443965                    Primary Immune Thrombocytopenia       TREATMENT   \n","447762          Postural Orthostatic Tachycardia Syndrome       TREATMENT   \n","451446                      Generalized Myasthenia Gravis       TREATMENT   \n","457340                    Primary Immune Thrombocytopenia       TREATMENT   \n","465975                  Multifocal Motor Neuropathy (MMN)       TREATMENT   \n","466710                             Membranous Nephropathy       TREATMENT   \n","483658            Pemphigus Vulgaris, Pemphigus Foliaceus       TREATMENT   \n","485813                     Congenital Myasthenic Syndrome         Unknown   \n","\n","                                            Interventions  \\\n","3942                                             ARGX-113   \n","16770                                            ARGX-113   \n","48185                               Efgartigimod, Placebo   \n","52828   efgartigimod PH20 SC in stage B, placebo in st...   \n","55111                                   ARGX-119, Placebo   \n","71310                               ARGX-113 with rHuPH20   \n","91603                                   ARGX-113, Placebo   \n","93450                                             Unknown   \n","108800              Efgartigimod PH20 SC, Placebo PH20 SC   \n","119169                               efgartigimod PH20 SC   \n","119245  ARGX-117, Placebo, ARGX-117 + rHuPH20, placebo...   \n","128354                               Efgartigimod PH20 SC   \n","135768                                           ARGX-113   \n","145591                                       efgartigimod   \n","148719                                        EFG PH20 SC   \n","156362              Efgartigimod PH20 SC, Placebo PH20 SC   \n","162749                                  ARGX-113, Placebo   \n","168588                                  ARGX-119, Placebo   \n","178362          efgartigimod PH20 SC, placebo, Prednisone   \n","181712                              efgartigimod, Placebo   \n","188839                                    Efgartigimod IV   \n","203828                                       Efgartigimod   \n","206525                               efgartigimod PH20 SC   \n","238957          efgartigimod PH20 SC, Placebo, prednisone   \n","242557                       Empasiprubart IV, Placebo IV   \n","248166                              efgartigimod, Placebo   \n","261810            Efgartigimod IV or Efgartigimod PH20 SC   \n","276571                                           ARGX-110   \n","284369  Efgartigimod concentrate for solution for infu...   \n","287036                   efgartigimod PH20 SC, Prednisone   \n","302451              Efgartigimod PH20 SC, Placebo PH20 SC   \n","309956                                   EFG PH20 SC, PBO   \n","331329                                    Efgartigimod IV   \n","352764                                       efgartigimod   \n","355889              efgartigimod IV, efgartigimod PH20 SC   \n","356425                                           ARGX-111   \n","361692                                       Efgartigimod   \n","364433                           efgartigimod IV, Placebo   \n","364648                                       Efgartigimod   \n","381128  efgartigimod PH20 SC as a prefilled syringe pr...   \n","385626                                  ARGX-117, Placebo   \n","393865                Efgartigimod, Placebo, PNEUMOVAX 23   \n","402726                               Efgartigimod PH20 SC   \n","422773                                  ARGX-117, Placebo   \n","431641                        Efgartigimod IV, Placebo IV   \n","432758              efgartigimod PH20 SC, efgartigimod IV   \n","443965                                       efgartigimod   \n","447762                              Efgartigimod, Placebo   \n","451446                                  ARGX-113, Placebo   \n","457340                                  ARGX-113, Placebo   \n","465975                                  ARGX-117, Placebo   \n","466710                           efgartigimod IV, placebo   \n","483658                   efgartigimod PH20 SC, prednisone   \n","485813                                            Unknown   \n","\n","                                 Intervention Description       Study Type  \\\n","3942           intravenous or subcutaneous administration   INTERVENTIONAL   \n","16770              Intravenous administration of ARGX-113   INTERVENTIONAL   \n","48185   Patients receiving efgartigimod infusions, Pat...   INTERVENTIONAL   \n","52828   Stage A: efgartigimod PH20 SC, Stage B: efgart...   INTERVENTIONAL   \n","55111   Patients receiving ARGX-119 IV or SC, Patients...   INTERVENTIONAL   \n","71310   subcutaneous administration of efgartigimod wi...   INTERVENTIONAL   \n","91603                                    Unknown, Unknown   INTERVENTIONAL   \n","93450                                             Unknown    OBSERVATIONAL   \n","108800  Subcutaneous efgartigimod PH20 SC given by pre...   INTERVENTIONAL   \n","119169   Subcutaneous injection with efgartigimod PH20 SC   INTERVENTIONAL   \n","119245  Subjects treated with ARGX-117, Subjects treat...   INTERVENTIONAL   \n","128354                            Subcutaneous injections   INTERVENTIONAL   \n","135768  human IgG1-derived Fc fragment that binds to h...   INTERVENTIONAL   \n","145591            an intravenous infusion of efgartigimod  EXPANDED_ACCESS   \n","148719  Subcutaneous injection of efgartigimod coformu...   INTERVENTIONAL   \n","156362  Subcutaneous efgartigimod PH20 SC given by pre...   INTERVENTIONAL   \n","162749                                   Unknown, Unknown   INTERVENTIONAL   \n","168588  Intravenous infusion of ARGX-119, Intravenous ...   INTERVENTIONAL   \n","178362  Subcutaneous injection of efgartigimod coformu...   INTERVENTIONAL   \n","181712  Intravenous infusion of efgartigimod, Intraven...   INTERVENTIONAL   \n","188839               Intravenous infusion of efgartigimod   INTERVENTIONAL   \n","203828  Participants will receive efgartigimod IV 10 m...   INTERVENTIONAL   \n","206525   Subcutaneous injection with efgartigimod PH20 SC   INTERVENTIONAL   \n","238957  Subcutaneous injection of efgartigimod using r...   INTERVENTIONAL   \n","242557  Intravenous infusion with Empasiprubart IV, In...   INTERVENTIONAL   \n","248166  Intravenous infusion of efgartigimod, Intraven...   INTERVENTIONAL   \n","261810  Intravenous infusion of Efgartigimod or Subcut...   INTERVENTIONAL   \n","276571                                            Unknown   INTERVENTIONAL   \n","284369  Patients receiving efgartigimod IV treatment i...   INTERVENTIONAL   \n","287036  Subcutaneous injection of efgartigimod coformu...   INTERVENTIONAL   \n","302451  Subcutaneous injection with efgartigimod PH20 ...   INTERVENTIONAL   \n","309956  Subcutaneous injection of efgartigimod coformu...   INTERVENTIONAL   \n","331329               Intravenous infusion of Efgartigimod   INTERVENTIONAL   \n","352764                                       efgartigimod    OBSERVATIONAL   \n","355889  intravenous infusions of efgartigimod, subcuta...   INTERVENTIONAL   \n","356425                                            Unknown   INTERVENTIONAL   \n","361692          Patients receiving efgartigimod infusions   INTERVENTIONAL   \n","364433      infusion of efgartigimod, infusion of placebo   INTERVENTIONAL   \n","364648                              Efgartigimod IV or SC    OBSERVATIONAL   \n","381128  efgartigimod PH20 SC as a prefilled syringe pr...   INTERVENTIONAL   \n","385626  Intravenous administration of ARGX-117, Intrav...   INTERVENTIONAL   \n","393865  intravenous infusion of efgartigimod, intraven...   INTERVENTIONAL   \n","402726        Subcutaneous administration of efgartigimod   INTERVENTIONAL   \n","422773  Intravenous administration of ARGX-117, Intrav...   INTERVENTIONAL   \n","431641  Intravenous infusion of efgartigimod, Intraven...   INTERVENTIONAL   \n","432758  Subcutaneous injection with efgartigimod PH20 ...   INTERVENTIONAL   \n","443965               Intravenous infusion of efgartigimod   INTERVENTIONAL   \n","447762  Efgartigimod IV 10 mg/kg infusion qw for 24 we...   INTERVENTIONAL   \n","451446  Intravenous administration of ARGX-113, Intrav...   INTERVENTIONAL   \n","457340  ARGX-113 (Dose A or Dose B) or matching placeb...   INTERVENTIONAL   \n","465975  Intravenous administration of ARGX-117, Intrav...   INTERVENTIONAL   \n","466710      infusion of efgartigimod, infusion of placebo   INTERVENTIONAL   \n","483658  Subcutaneous injection of efgartigimod using r...   INTERVENTIONAL   \n","485813                                            Unknown    OBSERVATIONAL   \n","\n","                Phases                                    Outcome Measure  \\\n","3942            PHASE1     bioavailability of a s.c. ARGX-113 formulation   \n","16770           PHASE3  Number of Participants With Treatment-Emergent...   \n","48185           PHASE2  Proportion of CRESS responders on ≥3 of 5 item...   \n","52828           PHASE2  Stage A: Percentage of patients with confirmed...   \n","55111           PHASE1  Number of treatment-emergent adverse events (T...   \n","71310           PHASE1  IgG levels of four different subcutaneous dose...   \n","91603           PHASE2  Number of Patients With Treatment Emergent Adv...   \n","93450          Unknown  To characterize MMN patient profiles for parti...   \n","108800          PHASE3  Percentage of participants who were proptosis ...   \n","119169          PHASE3  Incidence, frequency, and severity of adverse ...   \n","119245          PHASE1                                    Number of (S)AE   \n","128354          PHASE3  Efgartigimod serum concentrations as input for...   \n","135768          PHASE2  Safety and tolerability as measured by the inc...   \n","145591         Unknown                                            Unknown   \n","148719          PHASE3  Incidence treatment-emergent adverse events an...   \n","156362          PHASE3  Percentage of participants who were proptosis ...   \n","162749          PHASE1  Number of (related) treatment emergent AE of s...   \n","168588          PHASE1                 Assessment of adverse events (AEs)   \n","178362  PHASE2, PHASE3  Proportion of participants who are in complete...   \n","181712          PHASE3  Number of cumulative weeks over the planned 24...   \n","188839          PHASE1                  Efgartigimod PK parameters (Cmax)   \n","203828          PHASE2                   Incidence and severity of AESIs.   \n","206525          PHASE3  Incidence and severity of Adverse Events (AEs)...   \n","238957          PHASE3  Proportion of Pemphigus Vulgaris (PV) particip...   \n","242557          PHASE2  Incidence and severity of adverse events (AEs)...   \n","248166          PHASE3  Proportion of patients with chronic ITP with a...   \n","261810  PHASE2, PHASE3  Incidence of adverse events (AEs) Severity of ...   \n","276571          PHASE1                       Incidence and grading of AEs   \n","284369          PHASE3  Mean of the average Myasthenia Gravis - Activi...   \n","287036          PHASE3  Incidence of treatment-emergent adverse events...   \n","302451          PHASE3  Proportion of patients with chronic ITP with a...   \n","309956  PHASE2, PHASE3  Total improvement score (TIS); measured on a [...   \n","331329  PHASE2, PHASE3  Efgartigimod concentrations as input for compa...   \n","352764         Unknown  The overall long-term safety of efgartigimod i...   \n","355889          PHASE1  Percentage reduction in total IgG levels, comp...   \n","356425          PHASE1                             Dose-limiting toxicity   \n","361692          PHASE2  Number of participants with (serious) adverse ...   \n","364433          PHASE2  Change from baseline to week 24 in urine prote...   \n","364648         Unknown                                 Pregnancy outcomes   \n","381128          PHASE1  Primary PK parameters (Cmax) Primary PK parame...   \n","385626          PHASE2                    eGFR at 24 weeks posttransplant   \n","393865          PHASE1  Variation in the immune response assessed by c...   \n","402726          PHASE2  Incidence of treatment-emergent adverse events...   \n","422773          PHASE2  Safety outcomes based on adverse event (AE) mo...   \n","431641          PHASE3  Myasthenia Gravis Activities of Daily Living (...   \n","432758          PHASE3  Percent Change From Baseline in Total IgG Leve...   \n","443965          PHASE3  Frequency and severity of Adverse Events Frequ...   \n","447762          PHASE2  Evaluate the efficacy of efgartigimod in reduc...   \n","451446          PHASE3  Percentage of MG-ADL Responders During Cycle 1...   \n","457340          PHASE2  Incidence and severity of serious adverse even...   \n","465975          PHASE2  Safety outcomes based on adverse event (AE) mo...   \n","466710          PHASE2  Change from baseline to week 24 in urine prote...   \n","483658          PHASE3  Incidence of Treatment-Emergent Adverse Events...   \n","485813         Unknown  Summary statistics of retrospective and prospe...   \n","\n","                                 Medical Subject Headings  \n","3942                                              Unknown  \n","16770           Myasthenia Gravis Muscle Weakness Paresis  \n","48185                         Sjogren's Syndrome Syndrome  \n","52828   Polyneuropathies Polyradiculoneuropathy, Chron...  \n","55111                                             Unknown  \n","71310                                             Unknown  \n","91603           Myasthenia Gravis Muscle Weakness Paresis  \n","93450                                            Neuritis  \n","108800  Eye Diseases Graves Ophthalmopathy Thyroid Dis...  \n","119169  Thrombocytopenia Purpura, Thrombocytopenic, Id...  \n","119245                                            Unknown  \n","128354                  Myasthenia Gravis Muscle Weakness  \n","135768                                          Pemphigus  \n","145591                  Myasthenia Gravis Muscle Weakness  \n","148719  Muscular Diseases Dermatomyositis Myositis Pol...  \n","156362  Eye Diseases Graves Ophthalmopathy Thyroid Dis...  \n","162749                                            Unknown  \n","168588  Lambert-Eaton Myasthenic Syndrome Myasthenic S...  \n","178362                                Pemphigoid, Bullous  \n","181712  Thrombocytopenia Purpura, Thrombocytopenic, Id...  \n","188839                                Renal Insufficiency  \n","203828  Postural Orthostatic Tachycardia Syndrome Tach...  \n","206525                  Myasthenia Gravis Muscle Weakness  \n","238957                                          Pemphigus  \n","242557                           Dermatomyositis Myositis  \n","248166  Thrombocytopenia Purpura, Thrombocytopenic, Id...  \n","261810                  Myasthenia Gravis Muscle Weakness  \n","276571                           Nasopharyngeal Carcinoma  \n","284369                  Myasthenia Gravis Muscle Weakness  \n","287036                                Pemphigoid, Bullous  \n","302451  Thrombocytopenia Purpura, Thrombocytopenic, Id...  \n","309956  Muscular Diseases Dermatomyositis Myositis Pol...  \n","331329                  Myasthenia Gravis Muscle Weakness  \n","352764                                  Myasthenia Gravis  \n","355889                                            Unknown  \n","356425                                            Unknown  \n","361692                        Sjogren's Syndrome Syndrome  \n","364433                          Nephritis Lupus Nephritis  \n","364648                                  Myasthenia Gravis  \n","381128                                            Unknown  \n","385626                             Delayed Graft Function  \n","393865                                            Unknown  \n","402726  Polyneuropathies Polyradiculoneuropathy, Chron...  \n","422773                                           Neuritis  \n","431641                  Myasthenia Gravis Muscle Weakness  \n","432758                  Myasthenia Gravis Muscle Weakness  \n","443965  Thrombocytopenia Purpura, Thrombocytopenic, Id...  \n","447762  Postural Orthostatic Tachycardia Syndrome Tach...  \n","451446          Myasthenia Gravis Muscle Weakness Paresis  \n","457340  Thrombocytopenia Purpura, Thrombocytopenic, Id...  \n","465975                                           Neuritis  \n","466710     Kidney Diseases Glomerulonephritis, Membranous  \n","483658                                          Pemphigus  \n","485813  Lambert-Eaton Myasthenic Syndrome Myasthenic S...  "]},"execution_count":61,"metadata":{},"output_type":"execute_result"}],"source":["closest_orgs = find_closest_organizations('sare',n= n)\n","df = clin_trials_ro\n","df['Organization Full Name'] = df['Organization Full Name'].str.lower()\n","df.head(1)\n","df[df['Organization Full Name'].isin(closest_orgs)]"]},{"cell_type":"code","execution_count":62,"id":"cb216b75","metadata":{"execution":{"iopub.execute_input":"2024-06-14T18:10:43.764148Z","iopub.status.busy":"2024-06-14T18:10:43.763767Z","iopub.status.idle":"2024-06-14T18:10:44.03994Z","shell.execute_reply":"2024-06-14T18:10:44.038759Z"},"papermill":{"duration":0.300657,"end_time":"2024-06-14T18:10:44.042243","exception":false,"start_time":"2024-06-14T18:10:43.741586","status":"completed"},"tags":[]},"outputs":[{"data":{"text/html":["<div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>Organization Full Name</th>\n","      <th>Organization Class</th>\n","      <th>Responsible Party</th>\n","      <th>Brief Title</th>\n","      <th>Full Title</th>\n","      <th>Overall Status</th>\n","      <th>Start Date</th>\n","      <th>Standard Age</th>\n","      <th>Conditions</th>\n","      <th>Primary Purpose</th>\n","      <th>Interventions</th>\n","      <th>Intervention Description</th>\n","      <th>Study Type</th>\n","      <th>Phases</th>\n","      <th>Outcome Measure</th>\n","      <th>Medical Subject Headings</th>\n","      <th>Organization Full name</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","  </tbody>\n","</table>\n","</div>"],"text/plain":["Empty DataFrame\n","Columns: [Organization Full Name, Organization Class, Responsible Party, Brief Title, Full Title, Overall Status, Start Date, Standard Age, Conditions, Primary Purpose, Interventions, Intervention Description, Study Type, Phases, Outcome Measure, Medical Subject Headings, Organization Full name]\n","Index: []"]},"execution_count":62,"metadata":{},"output_type":"execute_result"}],"source":["filter_df('TriReme')"]},{"cell_type":"markdown","id":"e4b1a655","metadata":{"papermill":{"duration":0.020816,"end_time":"2024-06-14T18:10:44.084176","exception":false,"start_time":"2024-06-14T18:10:44.06336","status":"completed"},"tags":[]},"source":["# Future USE CASE \n","### With similar code an automated report similar studies could be sent to relevant employees monthly, weekly, etc... With adjustments, this can be done with or without specifying the organization. And would be more efficient if condition was known ahead of time. "]},{"cell_type":"code","execution_count":null,"id":"67194051","metadata":{"papermill":{"duration":0.020926,"end_time":"2024-06-14T18:10:44.126661","exception":false,"start_time":"2024-06-14T18:10:44.105735","status":"completed"},"tags":[]},"outputs":[],"source":[]}],"metadata":{"colab":{"provenance":[]},"kaggle":{"accelerator":"none","dataSources":[{"datasetId":5135511,"sourceId":8586221,"sourceType":"datasetVersion"}],"dockerImageVersionId":30715,"isGpuEnabled":false,"isInternetEnabled":true,"language":"python","sourceType":"notebook"},"kernelspec":{"display_name":"Python 3","language":"python","name":"python3"},"language_info":{"codemirror_mode":{"name":"ipython","version":3},"file_extension":".py","mimetype":"text/x-python","name":"python","nbconvert_exporter":"python","pygments_lexer":"ipython3","version":"3.10.13"},"papermill":{"default_parameters":{},"duration":2417.670689,"end_time":"2024-06-14T18:10:45.376529","environment_variables":{},"exception":null,"input_path":"__notebook__.ipynb","output_path":"__notebook__.ipynb","parameters":{},"start_time":"2024-06-14T17:30:27.70584","version":"2.5.0"}},"nbformat":4,"nbformat_minor":5}